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INTEGRIN α6β4 PROMOTES PANCREATIC CANCER INVASION BY ALTERING 
DNA REPAIR-MEDIATED EPIGENETICS 
 
Integrin α6β4 is upregulated in pancreatic carcinoma, where signaling promotes 
metastatic properties, in part by altering the transcriptome. Such alterations can be 
accomplished through DNA demethylation of specific promoters, as seen with the pro-
metastatic gene S100A4. I found that signaling from integrin α6β4 dramatically 
upregulates expression of amphiregulin (AREG) and epiregulin (EREG), ligands for the 
epidermal growth factor receptor (EGFR), and that these ligands promote pancreatic 
carcinoma invasion. To determine if AREG and EREG are regulated by DNA 
methylation, pancreatic cancer cells with low AREG and EREG expression were treated 
with the DNA methyltransferase inhibitor 5-aza-2’-deoxycytidine (5-Aza-CdR), resulting 
in stable overexpression of AREG and EREG, and this induction required signaling from 
integrin α6β4. Similarly, treatment of cells with high integrin α6β4 with the methyl donor 
S-adenosylmethionine inhibited gene expression of AREG and EREG. Whole genome 
bisulfite sequencing on pancreatic cancer cells reveled hypomethylation of the promoter 
regions of AREG and EREG when integrin α6β4 is high, and these regions correspond to 
H3K27Ac, indicative of enhancer location. Interestingly, I also observed genome-wide 
DNA demethylation, and a large proportion of altered CpGs correspond to potential 
enhancers. It is currently accepted that active DNA demethylation occurs via DNA repair. 
I tested this hypothesis by treating cells with Gemcitabine, which inhibits multiple 
components of DNA repair, including DNA demethylation mediated by GADD45A. 
Gemcitabine treatment resulted in marked reduction in AREG and EREG expression. To 
further test the involvement of GADD45A, I used RNAi-mediated knockdown or cDNA 
overexpression to alter GADD45A levels. In both instances, AREG and EREG 
expression positively correlated with GADD45A, particularly when integrin α6β4 is high, 
indicating that GADD45A is a rate-limiting step in AREG and EREG overexpression. 
Similarly, using stable shRNA, I show that Thymine DNA Glycosylase (TDG), and 
TET1 known modulators of DNA demethylation, are required for AREG and EREG 
expression in integrin α6β4 high cells, and nuclear localization of TDG is much higher in 
cells with high integrin α6β4. Using a specific inhibitor I found that AREG and EREG 
expression is dependent on Parp-1. Finally, I determined that integrin α6β4 signaling 
enhances cells ability to respond to and survive in the presence of DNA damage, and that 
 active DNA repair is required for integrin α6β4 mediated DNA demethylation. Taken 
together, these data indicate that DNA repair is required to maintain overexpression of 
AREG and EREG in response to signaling from integrin α6β4 and that integrin α6β4 
promotes this overexpression by enhancing DNA repair. 
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Cancer, EGFR signaling 
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CHAPTER 1: INTRODUCTION 1 
1.1 Integrin Signaling and Function in Normal Tissues 
Integrins were classified as a family in 1987 by Richard Hynes and since have 
become the most well studied cell surface receptors [1, 2]. Integrins are heterodimeric 
transmembrane proteins whose critical function is cellular adhesion to the extracellular 
matrix (ECM) and attachment to other cells. Through these contacts, integrins contact the 
ECM and directly bind the intracellular cytoskeleton, where these interactions modify 
actin and intermediate filaments [3, 4]. Additionally, integrins are highly utilized 
signaling molecules by cells as binding and integrin activation stimulates a vast number 
of signaling networks on the interior of the cell [5]. Integrin signaling affords the ECM 
the ability to alter cellular responses such as survival, proliferation, motility, tension on 
the ECM, and even ECM content [6].  
Integrins are composed of a non-covalently linked single α and single β subunit, of 
which eighteen α and eight β subunits have been identified in mammals, and twenty-four 
combinations of integrin receptors have been characterized [1]. Every cell type has a 
unique set of integrin combinations that are expressed on the cell surface and contribute 
to cellular response to environmental stimuli. A vast number of ligands bind to integrin 
receptors including ECM proteins such as laminin, collagen, fibronectin, and vitronectin 
and combinations of integrins have overlapping substrate specificity [7].  
                                                 
1 Part of this research was originally published in The Journal of Biological Chemistry. 
Brittany L. Carpenter, Min Chen, Teresa Knifley, Kelley A. Davis, Susan M. W. 
Harrison, Rachel L. Stewart, Kathleen L. O’Connor. Integrin α6β4 Promotes Autocrine 
Epidermal Growth Factor Receptor (EGFR) Signaling to Stimulate Migration and 
Invasion toward Hepatocyte Growth Factor (HGF). Journal of Biological Chemistry. 
2015; 290(45):27228-38. © the American Society for Biochemistry and Molecular 
Biology.  
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My study focused on a laminin binding integrin found on the surface of most 
epithelial tissues, integrin α6β4 [8]. The α6 integrin has two binding partners, integrin β1 
and integrin β4, whereas the β4 integrin can only pair with integrin α6, therefore 
throughout this study, modulation of integrinβ4 subunit effectively alters the entire 
complex [9]. While most integrin receptors contain large extracellular domains and short 
cytoplasmic tails, the β4 subunit of integrin α6β4 has a long cytoplasmic signaling 
domain of nearly 1000 amino acids [10].  Although, integrins have no intrinsic enzymatic 
activity, the β4 cytoplasmic tail contains fibronectin type III repeats that allow this tail to 
act as a signaling platform for recruitment of complexes responsible for activation of 
downstream signaling pathways [11].  
Integrin α6β4 is expressed in epithelial cells where its primary function is to maintain 
the integrity of epithelial monolayers through the formation of stable adhesive structures, 
termed hemidesmosomes [12]. Hemidesmosomes are responsible for attachment of cells 
to the basement membrane, and integrin α6β4, in cooperation with plectin, BP180, 
BP230 and tetraspanins serves as the core complex mediating adhesion between the 
extracellular matrix and cellular cytoskeleton [13]. Integrin α6β4 is the key component 
responsible for binding laminin in the basement membrane, while interactions with 
plectin mediate binding to intracellular intermediate filaments [3]. A single mutation in 
any one of the twelve different hemidesmosome genes result in skin blistering and loss of 
epithelial lining such as the gastrointestinal tract, trachea, and cornea, demonstrating their 
importance [14, 15]. Not only are hemidesmosomes critical for stable adhesion of cells 
but they are also necessary for maintaining apical-basal cell polarity [12]. During normal 
cellular processes such as differentiation and wound healing, hemidesmosomes are 
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dissolved and cells are released [12]. Additionally, this breakdown of hemidesmosomes 
occurs during carcinoma progression, when cells lose their ability to tightly bind, and 
now have a motile phenotype [14]. It is this loss of these stable contacts that releases 
integrin α6β4, allowing it to interact with the actin cytoskeleton and signal to promote 
tumorigenic properties.   
1.2 Integrin α6β4 and Pancreatic Cancer Progression 
Integrin signaling is a fundamental component of cancer progression, as it is critical 
for activation and integration of signaling networks through pro-oncogenic pathways. Of 
the 24 mammalian integrin receptors, integrin α6β4 is overexpressed in nearly all 
pancreatic carcinomas where it stimulates malignant progression by promoting tumor cell 
migration, invasion and cell survival [16, 17]. Pancreatic carcinoma is the fourth leading 
cause of cancer death among men and women in the US, with more than 90% of patients 
succumbing to their disease within 5-years [18]. This is due to an aggressive course of 
disease progression, as many patients are diagnosed with late stage metastatic disease, 
and lack of effective therapeutic options. Integrin α6β4 contributes to an overwhelming 
majority of the invasive characteristics of pancreatic carcinoma. Therefore, obtaining 
knowledge about the mechanistic function of this integrin will provide insight into the 
deadly nature of this disease.  
The role of integrin α6β4 in tumorigenic properties of cancer cells is manifested in 
two ways, a mechanical function and a signaling function. During the progression of 
cancer to a metastatic phenotype, stimulation of the Hepatocyte Growth Factor (HGF) 
receptor, MET, and the EGFR by their respective growth factor ligands promotes 
disassembly of hemidesmosomes in most epithelial tumors, causing the loss of stable 
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contacts, and therefore allowing cells to detach and migrate [19]. During this process 
integrin α6β4 is liberated from these tight hemidesmosomal adhesions and relocates 
across mobile cells by interacting with F-actin to support lamellipodia and filapodia 
formation, thus facilitating malignant cells to migrate and invade [20]. Additionally, 
dynamic contacts between integrin α6β4 and the ECM allow carcinoma cells to have 
traction as it moves through the body during the process of metastasis [21].  
The signaling capacity of integrin α6β4 has been widely demonstrated by the 
necessity for cooperative activation of integrin α6β4 with c-MET, RON, LPAR, and 
EGFR [22-24]. This activation of integrin α6β4 results in enhanced downstream signaling 
through growth factor receptor activated pathways such as PI3K, MAPK, Src family 
kinases, and the Rho family of small GTPases [25, 26], all of which promote pro-
oncogenic properties such as invasion, angiogenesis, anoikis-resistance, cell survival, and 
proliferation (reviewed in [27]). Work done in the O’Connor lab has found previously 
that integrin α6β4 contributes to these properties, in part, through specific transcriptional 
activation of pro-tumorigenic genes [28-31]. 
1.3 Integrin Signaling and Transcriptional Regulation 
Transcriptional regulation during tumorigenesis is one of the critical components in 
tumor initiation, progression, and colonization of metastatic sites. Downregulation of 
tumor-suppressors and activation of oncogenes have the capability to dramatically shift 
the transcriptome to a more permissive state for cancer cell survival, stem cell state, 
growth, angiogenesis, and metastatic potential [32]. Signaling from the tumor 
microenvironment can result in both genome-wide and gene-specific alterations in 
transcription that lead to malignant progression. Integrins, as the major sensor of the 
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tumor microenvironment, and the link between the ECM and internal cell networks, may 
hold the key to transcriptional alterations in response to environmental signals, 
specifically during metastatic cancer progression. Toker and colleagues established that 
integrin α6β4 signaling results in activation of the Nuclear Factor of Activated T-cells 
(NFATs), transcription factors, to promote gene expression, that in turn contributes to 
cancer cell invasion [33]. In support of this work, Chen et al. identified the first targets of 
integrin α6β4 mediated NFAT activation, S100A4 and Autotaxin in breast carcinoma [30, 
34]. Furthermore, these studies demonstrated the robust ability of integrin α6β4 to 
dramatically alter the transcriptome, leading to the upregulation of key pro-invasion and 
metastatic genes. In my study, I found that integrin α6β4 stimulates the expression of 
EGFR ligands AREG and EREG, thus contributing to an invasive phenotype in 
pancreatic cancer cells.    
1.4 Epidermal Growth Factor Receptor and Associated Ligands in Pancreatic 
Cancer   
 In normal tissues, EGFR signaling is required for development of epithelial 
structures including lung, pancreas, skin, gastrointestinal tract, and the mammary gland 
[35, 36]. EGFR and associated EGF-like ligands become overexpressed or mutated in 
many cancers, including pancreatic, head and neck, breast, colorectal, lung, prostate, 
kidney, ovarian, brain, and bladder cancers [37]. Signaling through the EGFR pathway 
mediates multiple processes involved in tumor progression, including angiogenesis, 
invasion, migration, proliferation, and evasion of apoptosis [38]. Consequently, particular 
attention has been given to the role of the EGFR pathway in the development of 
malignant phenotypes, resulting in this pathway being targeted by a substantial array of 
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chemotherapeutics. Use of receptor blocking antibodies and tyrosine kinase inhibitors 
specific for EGFR family members, as monotherapy or in combination with other 
therapeutic agents, have been successful for colorectal, lung, and head and neck cancers, 
in terms of increasing overall survival and progression free survival [39-41] 
There are seven ligands known to bind and signal through EGFR: epidermal 
growth factor (EGF), transforming growth factor-α (TGFα), betacellulin, heparin-binding 
EGF-like growth factor, epigen, AREG, and EREG. Typically, after ligand binding, 
activated EGFR complexes are endocytosed, which leads to recruitment of the ubiquitin 
ligase c-Cbl. Recruitment of c-Cbl promotes ubiquitination, lysosomal targeting, and 
degradation of EGFR [42]. However, AREG and EREG are unique in their downstream 
signaling following ligand-receptor binding. Binding of AREG or EREG to EGFR results 
in a transient recruitment of c-Cbl to EGFR and a reduced level of ubiquitination. This 
property permits EGFR recycling back to the plasma membrane where it may be 
continually activated [43, 44]. As a result, AREG and EREG have been strongly 
implicated in tumor progression. 
EGFR ligands are integral membrane pro-proteins that can participate in 
juxtacrine signaling. However, the more common mechanism is that once these ligands 
are cleaved and released into the extracellular environment, they act in a paracrine and 
autocrine manner [45]. For AREG, this occurs when disintegrin and metalloproteinase 
containing protein 17 (ADAM-17)/ tumor necrosis factor α converting enzyme (TACE) 
[46] or matrix metalloproteinase-1 (MMP1) [47] cleaves the membrane precursor pro-
AREG. This release creates feedback loops in primary and metastatic sites to promote 
tumor progression. AREG may also enter the bloodstream and travel to distant organs, 
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acting as an endocrine signal [48], and thus potentially creating a favorable 
microenvironment [49]. This property allows tumors to maintain a high rate of 
proliferation with a reduced requirement for exogenously supplied growth factors [38]. 
Notably, AREG has been demonstrated to stimulate proliferation of pancreatic ductal 
cells and associate with an increased frequency of lymph node involvement in pancreatic 
cancer patients [50]. Lastly, AREG can induce EGF-independent cell growth by acting as 
a self-sufficient growth signal in serum-free conditions [51, 52]. Likewise, EREG 
expression is upregulated in pancreatic cancer and contributes to cell growth by binding 
to EGFR through paracrine and autocrine loops [53]. Similar to AREG, EREG is also 
cleaved at the cell membrane by ADAM-17/TACE [46]. Once released, EREG is unique 
in its ability to stimulate the majority of the ErbB heterodimer receptor combinations 
[54]. While the affinity of EREG to EGFR is lower compared to other EGFR ligands, its 
signaling potency is higher, thus making EREG a more effective signaling ligand [54].  
1.5 Epigenetic Regulation  
Every cell in the human body has the same genetic sequence, however, regulation of 
transcriptomic patterns defines cell type, cellular function and elicited cellular responses. 
Activation by transcription factors, in addition to stable changes in covalent 
modifications to DNA and packaging of DNA are critical for determining gene 
expression patterns, both in a normal developmental and in a diseased state. During 
differentiation, epigenetic regulation is responsible for establishing long-term gene 
expression patterns, which determine cell lineage and fate. Epigenetics is currently 
defined as heritable changes in gene expression, not associated with changes in gene 
sequence [55]. Epigenetic regulation allows for dynamic alterations in gene expression 
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associated with cellular environment. Furthermore, the reversible nature of epigenetic 
modification makes it an attractive target for therapies. 
The human genome contains over 3 billion base pairs of DNA that must be efficiently 
packaged to fit in the nucleus of every cell [56]. While this compaction creates genomic 
stability, it also limits the ability of regulatory elements to bind and activate gene 
expression. Therefore, epigenetic modification allows for dynamic opening and closing 
of the chromatin, thus contributing to specific gene expression [57]. Nucleosomes are 
responsible for packaging the DNA into chromatin and consist of two each of histone 
proteins H2A, H2B, H3, and H4 [58, 59]. Nucleosomes have high affinity for DNA, 
wrapping 146 bps around each, and in cooperation with linker histones and architectural 
proteins compacts the DNA into higher order structures [60]. Movement of nucleosomes 
by ATPase dependent remodeling complexes alters nucleosome position and therefore 
overall chromatin compaction. Modifications of histone proteins within the nucleosome 
impact the affinity of DNA for the nucleosome and can recruit transcriptional regulators. 
Lastly, DNA methylation contributes to chromatin compaction in the form of covalent 
modifications to DNA bases. Together these three components are responsible for 
reversibly altering accessibility to transcription factors, and taken together make up the 
field of epigenetics. Establishment of these epigenetic factors is what ensures proper gene 
regulation during development, in different tissue types, during cellular responses, and in 
the context of this study, tumor progression and metastasis.  
To produce full-blown metastatic disease, cancer cells require both genetic and 
substantial epigenetic changes. Initial evidence for the importance of epigenetic 
alterations was demonstrated by the dramatic differences in epigenetic modifications 
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between normal tissue, tumor tissue, and metastatic disease [61-63]. Aberrant epigenetic 
modification is a dynamic process that contributes to a continually changing 
transcriptome in cancer cells, and is ultimately the driving force for many oncogenes.  
1.5.1 Chromatin Remodeling and Cancer 
Chromatin remodeling is necessary for proper transcriptional regulation and 
maintenance of genomic stability. Chromatin exists in two states: condensed 
heterochromatin, which is transcriptionally silent and euchromatin, which is 
transcriptionally active and in a more dynamic, “breathable” state [64]. Currently, four 
families of chromatin remodelers have been identified: SWI/SNF, INO80, ISWI, and 
NuRD/Mi-2, all of which have the ability to interact with the histones and the DNA. 
These remodelers also have innate ATPase activity, as energy is required to move 
nucleosome position along DNA, and exchange histone variants within the nucleosome 
[65]. The contributions of each chromatin remodeling family to cancer progression are 
briefly summarized below. 
The SWI/SNF complex provides access for the transcriptional machinery by 
destabilizing chromatin structures using ATP hydrolysis. The broad reaching impacts of 
the SWI/SNF complex in cancer is evidenced by the finding that more than 20% of all 
cancers harbor a mutation in this complex [66]. Interestingly, loss of the core component 
SNF5 of this 8-11 protein complex in mice resulted in T-cell lymphoma or rhabdoid 
tumor formation in 100% of mice with a median onset of only 11 weeks [67].  Also, 
studies done in vitro demonstrate that BRCA1 and pRB interact with the SWI/SNF 
components BRG1 and BRM to contribute to breast cancer [68]. However, while the 
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importance of SWI/SNF remodeling complexes has been well studied, the mechanism for 
how these complexes directly promote cancer progression is still under investigation.  
INO80 and ISWI complexes function during DNA damage where chromatin 
remodelers are recruited to sites of damage to facilitate availability of DNA substrates for 
repair enzymes. INO80 and ISWI complexes act during double strand breaks where they 
facilitate homologous recombination and non-homologous end joining [69, 70].  INO80 
is recruited to double strand breaks through binding of the histone variant H2AX which 
is activated immediately after DNA insult [71]. ISWI containing remodelers also function 
during single strand lesion, which get repaired by either nucleotide excision repair (NER) 
or base excision repair (BER) [70]. This function of chromatin remodeling during the 
DNA damage response could play a major role in the ability of cells to respond to 
chemotherapies, as many of these elicit a DNA repair cascade.  
Lastly, the nucleosome remodeling deacetylase (NuRD) complex contains seven 
subunits and has intrinsic ATPase dependent remodeling and histone deacetylase activity, 
making this complex unique in its ability to couple two independent epigenetic modifiers 
[72]. The metastasis-associated gene (MTA) is a component of the NuRD complex and is 
well known for its role in enhancing invasive properties of cancer, including breast, 
colorectal, gastric, lung, ovarian, prostate, and head and neck [73]. Additionally, NuRD 
has been found in complex with the TWIST transcription factor in breast cancer cells 
[74]. TWIST is known as a master transcription factor and for its ability to induce the 
epithelial to mesenchymal transition (EMT) and therefore promote metastatic growth 
[75]. The importance of NuRD in tumor carcinogenesis is also demonstrated by its ability 
to bind the retinoic acid receptor, target tumor-suppressor genes and recruit other 
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repressive epigenetic modifiers including the DNA methyltransferases [76]. Taken 
together, these examples of chromatin modifiers in cancer demonstrate the vast ability of 
epigenetics to impact tumor progression. Chromatin remodelers in turn are also 
dependent on and have the ability to impact histone modifications. 
1.5.2 Histone Modifications and Cancer 
As mentioned previously, nucleosomes are composed of a histone octamer, and 
post translational modifications of these histones impact the affinity of the nucleosome 
for DNA, as well as the ability of chromatin remodelers, DNA methyltransferases, and 
histone specific enzymes to bind [77]. Histones contain N-terminal tails available for 
modification at specific residues where they can be phosphorylated, methylated, 
acetylated, ubiquitinated, or sumoylated, all of which promote an active or repressive 
transcriptional state [78]. Initial studies examining global histone modifications in cancer 
found that acetylation of lysine 16 of histone H4 (H4K16ac) and tri-methylation of lysine 
20 at histone H4 (H4K20me3) was lost in tumor vs. normal tissues, and this was common 
across many cancer types [62]. Other changes in histone patterns are more specific for 
cancer type, such as decreased H3K20 methylation in bladder cancer [79], reduced 
H3K4me2 and H3K9ac in breast cancer, and increased H3K9me2 in colorectal neoplastic 
cells compared to normal tissue [80]. Interestingly, these aberrant modification patterns 
are currently targets for epigenetic drugs such as the histone deacetylase inhibitors 
Trichostatin A (TSA) and Vorinostat, which attempt to reestablish a “normal” histone 
code. These altered epigenetic modifications do have the potential to act as predictive 
biomarkers for cancer progression, survival, and therapeutic response. When coupled 
with gene expression data a cancer’s unique histone code may provide a comprehensive 
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view of epigenetic alterations and provide insight into an appropriate course of action for 
individual patients.  
1.5.3 DNA Methylation and Cancer  
DNA hypomethylation was the first epigenetic event described in tumors and 
aberrant DNA methylation patterns are considered a hallmark of malignant disease [81]. 
DNA methylation involves the covalent addition of a methyl group to the 5th carbon 
position on cytosine, primarily in the context of a CpG dinucleotide [81]. 5-
methylcytosine (5-mC) accounts for nearly 1% of all bases in the genome and 70-80% of 
all cytosines within the CpG context are methylated in somatic cells [82]. During 
embryonic development DNA methylation patterns are established by the de novo DNA 
methyltransferases (DNMTs), DNMT3a and DNMT3b [83]. DNA methylation is 
primarily maintained across multiple generations by the maintenance methyltransferase 
DNMT1, however recent studies have demonstrated that the DNMT3 family also 
contributes to maintenance methylation [84]. However, our traditional view of 
maintenance methylation is that DNMT1 is recruited to the replication fork where it 
recognizes hemi-methylated DNA, and replaces adjacent methyl groups on the nascent 
strand [83].  
While other epigenetic modifications are critical for gene expression, DNA 
methylation is the most well studied and considered the primary form of epigenetic 
information. Cancer genomes, in particular, demonstrate a reduction in genome wide 
methylation patterns, thus resulting in destabilization of many regions of chromatin by 
creating instability of transposable elements [85, 86]. Gene specific DNA demethylation 
contributes to the activation of oncogenes that directly promote metastatic disease, and 
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are otherwise silenced in somatic cells [87]. However, most studies examining DNA 
methylation have done so in the context of CpG islands, which are regions of DNA more 
than 200 base pairs (bp) long and having a higher G+C content and higher frequency of 
CpG sites than the rest of the genome [88]. CpG islands typically occur at transcription 
start sites (TSS), and are found at nearly half of all genes with the remainder equally 
distributed intragenically and intergenically [89]. CpG islands located in gene promoters 
of major tumor suppressor genes are often hypermethylated in cancer, thus creating a 
stable, long term block on their activity, including pRB, P16INK4A, VHL, hMLH1, and 
BRCA1 [90]. Furthermore, 5-mC has an increased rate of mutation to thymine, and 
accounts for about 1/3 of all disease causing mutations [91], including mutation of p53, 
thus acting as a major driver of cancer progression [92]. Interestingly, these findings 
implicate epigenetic mechanisms as causing some of the first “hits” in cancer initiation. 
Consequently, the importance of DNA methylation in carcinogenesis and it’s reversible 
nature makes DNA methylation ideal for targeted therapies [83]. Considering that 
epigenetic changes are reversible, DNA demethylating agents such as Azacitidine (the 
clinical equivalent of 5-aza-cytidine or 5-Aza) and Decitabine (5-Aza-2-deoxycitidine; 5-
Aza-CdR; DAC) have become commonly used therapies for the treatment of several 
types of cancer [93-95]; however, because of their non-specific nature, resistance to these 
types of drugs can still be a major problem. A possible mechanism for this resistance may 
be the activation of pro-metastatic genes along with tumor suppressor genes. A potential 
solution to this problem is identification of invasion and metastasis promoting pathways 
that become activated in response to DNA demethylation, so that they may be targeted 
alongside these epigenetic drugs. 
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1.6 Goals and Hypothesis for Dissertation 
It is well established that EGFR and associated ligands contribute to key steps in 
cancer growth and progression. Specifically, autocrine secretion of the ligands AREG 
and EREG increase the invasive and migratory capacity of cancer cells and can 
contribute to drug resistance [96, 97]. These molecules become upregulated throughout 
cancer progression and this is potentially the result of signaling through pro-metastatic 
pathways, such as those regulated by integrin α6β4. Integrin α6β4 is highly upregulated 
and activated in pancreatic carcinoma where it dramatically alters the transcriptome, in 
part through DNA demethylation of promoters of pro-tumorigenic molecules. DNA 
demethylation is most often achieved by enzymatic removal of the repressive methyl 
group coordinated by a DNA repair pathway. Therefore, considering that integrin α6β4 is 
a critical sensor of the tumor microenvironment, and contributes to gene regulation in 
cancer, DNA demethylation by DNA repair could provide insight into context dependent 
epigenetic alterations that contribute to metastatic disease. Consequently, the overall 
objective for this dissertation was to understand in mechanistic detail how integrin α6β4 
alters the overall state of DNA methylation in pancreatic cancer and in particular how 
integrin α6β4 contributes to specific upregulation of two EGFR ligands, AREG and 
EREG. I therefore, hypothesized that integrin α6β4 contributes to genome wide DNA 
demethylation and mediates gene specific expression of AREG and EREG through active 
DNA demethylation of their respective promoters. Additionally, I hypothesized that a 
DNA repair pathway mediated this site-specific DNA demethylation of AREG and 
EREG promoters. The following data chapters will address three specific project goals: 
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1) Define the role of integrin α6β4 signaling in the transcriptional 
upregulation of AREG and EREG and determine the impact of DNA demethylating 
drugs on the expression of these genes.  
 2) Examine genome-wide and gene specific alterations in DNA methylation 
mediated by integrin α6β4 using whole genome bisulfite sequencing (WGBS).  
 3) Determine the involvement of DNA repair pathways on transcriptional 
upregulation of AREG and EREG, downstream of integrin α6β4 signaling.  
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CHAPTER 2: MATERIALS AND METHODS 2 
2.1 Cell Lines and Cell Culturing 
Panc1, Suit2, AsPC1 and Panc1 clones with variable expression of integrin α6β4 
were used. The Panc1 cell line was previously sorted by FACS analysis for integrinβ4 
subunit to establish stable populations with varying integrin α6β4 expression [98]. Suit2, 
AsPC1 and Panc1-3D7 cells were used as high expressers of integrin α6β4. Panc1-2G6 is 
a low integrin α6β4 expressing cell line and Panc1-β4ΔCyt cells express a dominant 
negative form of integrin α6β4 [99]. Suit2 (obtained from Dr. Takeshi Iwamura, 
Miyazaki Medical College, Miyazaki, Japan) and AsPC1 cells (from America Type 
Culture Collection, ATCC) were maintained in RPMI 1640. Clones generated from 
Panc1 cells (from ATCC) were grown in Dulbecco’s modified Eagle’s medium (DMEM; 
high glucose). HEK293-LTV cells (obtained from Dr. Tianyan Gao, University of 
Kentucky) were used for lentivirus production and maintained in Dulbecco’s modified 
Eagle’s medium (high glucose). All media were supplemented with 10% Fetal Bovine 
Serum (Sigma Aldrich, St. Louis, MO), 1% penicillin, 1% streptomycin, and 1% l-
glutamine (GIBCO by Life Technologies, Grand Island, NY). 
2.2 Drug Treatment  
5-Aza-CdR (Sigma-Aldrich) was added to Panc1-2G6 (low β4), Panc1-3D7 (high 
β4), or Panc1-3D7 β4 shRNA cells in fresh medium daily at a final concentration of 1 
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μM or 5 μM for 3 or 5 days, while control cells were treated with dimethyl sulfoxide 
(DMSO). Cells were collected either immediately or for indicated experiments, kept in 
culture for 10 days and two passages post 5-Aza-CdR removal, as indicated. Suit2 and 
AsPC1 cells were treated with 80 μM S-adenosylmethionine (SAM; New England 
Biolabs, Ipswich, MA) in fresh medium daily for 5 days. Control cells were treated with 
an equivalent volume of vehicle (0.005 M H2SO4 and 10% EtOH.) Pancreatic cancer 
cells were treated with 250-500 nM JQ1 (Bradner Lab; Dana-Farber Cancer Institute) or 
DMSO for 16 hours. For experiments using Gemcitabine (Sigma-Aldrich) or 3,4-
Dihydro-5-[4-(1-piperidinyl)butoxyl]-1(2H)-isoquinolinone (DPQ; Sigma-Aldrich), 
Panc1-2G6 (β4 low) or Panc1-3D7 (β4 high) cells were treated with indicated 
concentration or equal volume vehicle control for 3 days. After treatment, cells were 
harvested and mRNA levels of AREG and EREG measured by Quantitative Real-Time 
Polymerase Chain Reaction (qPCR) as described below.  
2.3 Gene Knockdown by RNAi 
For siRNA treatment, cells from 70% confluent cultures were washed once with 
phosphate buffered saline (PBS), trypsinized, and washed three times by centrifugation 
with serum-free DMEM. Cells (3 x 106) were resuspended in 400 μl serum-free DMEM 
and electroporated without or with 200 nM non-targeting siRNA (Dharmacon, Inc.), or 
200 nM siRNA specific for NFAT5 or GADD45A as described previously [29]. Cells 
were then replated under normal culturing conditions and normal growth media was 
added 24 hours following electroporation. Cells were collected after 72 hrs and assessed 
for NFAT5, GADD45A, AREG and EREG expression by qPCR as described below. 
For stable knockdown of AREG, EREG, TDG, XPA, XPG, or XPF lentivirus was 
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produced by combining MISSION constructs for packaging (psPAX2), envelope 
(pDM2G) vectors and targeting shRNA or a non-targeting vector (pLKO.1), at a 4:2:1 
ratio (all vectors obtained from Sigma Aldrich, St. Louis, MO). Polyethylenimine (PEI; 
Polysciences) was combined with the DNA mixture at a 3:1, DNA to PEI ratio and added 
drop wise to 70% confluent HEK 293LTV cells that had been passaged 24 hrs prior to 
transfection. Conditioned media was collected 24 and 48 hrs post transfection, 
centrifuged at 2,000 x g for 10 mins and viral supernatant collected. Panc1-2G6 and 
Panc1-3D7 were passaged to 70% confluence in 10 cm dishes and 4 ml of viral 
supernatant added in combination with 8 μg/ml hexadimethrine bromide (polybrene, 
Sigma Aldrich). Viral supernatant was added again 24 hours later, and 48 hours later was 
replaced with normal growth media. Cells were placed under puromycin selection (2-4 
μg/ml) for a minimum of three days, or until cell death stopped occurring due to 
selection.  Gene expression was measured by qPCR 24 hrs following removal of 
puromycin, and migration and invasion assays performed immediately following 
confirmation of efficient knockdown of AREG and EREG.  
2.4 RNA Extraction and qPCR 
Cells from 70% confluent cultures were washed in 2 ml of PBS buffer (Gibco by 
Life Technologies) and harvested using 0.05% trypsin-EDTA. Total RNA was extracted 
using Trizol reagent and manufacturer’s protocol (Invitrogen, Carlsbad, CA). Chloroform 
was added and nucleic acids separated from protein by high-speed centrifugation (15,000 
x g for 10 min.). The organic phase was removed and equal volume isopropanol added to 
precipitate RNA. Samples were centrifuged, washed with 70% ethanol, and redissolved 
in an appropriate volume of nuclease-free water. RNA quantity was confirmed using a 
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Nanodrop 2000 spectrophotometer (Thermo Scientific) and purity determined by OD 
260:280 ratios, with a minimum requirement of 1.8. cDNA was synthesized using the 
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA) 
and 1 μg of total RNA. Expression of genes of interest was assessed by qPCR using 
available probes (Taqman; Applied Biosystems), reagents, and the StepOnePlus Real-
Time PCR System from Applied Biosystems. Triplicate CT values were analyzed in 
Microsoft Excel using the comparative CT (ΔΔCT) method as described by the 
manufacturer (Applied Biosystems). The amount of target cDNA (2-ΔΔCT) was 
determined by normalizing to the endogenous reference (18S or β-Actin) and relative to 
one of the experimental samples, either control treated, or those transfected with non-
targeting or empty vector for knockdown and overexpression studies. 
2.5 Migration and Invasion Assays  
Transwell chemotactic migration assays were performed as described previously 
(6.5-mm diameter, 8-µm pore size; Corning) [31]. Upper portions of Transwell chambers 
were coated with 15 µg/ml laminin-1 for migration assays or with 10 µg Matrigel (BD 
Biosciences) for invasion assays. For all assays, the bottom chambers of Transwells were 
coated with 15 µg/ml laminin-1. Following coating with laminin or Matrigel, wells were 
washed three times with serum-free media containing 250 µg/ml bovine serum albumin 
(BSA). Cells were trypsinized, collected from 70% confluent cultures, washed three 
times with serum-free media, and counted using a ViCell Coulter Counter (Beckman 
Coulter).  A single cell suspension (5 x 104) was placed into the top Transwell chamber 
and allowed to migrate for 4 hrs or invade for 6 hrs towards 10 ng/ml HGF, which was 
placed in the bottom chamber. Cells that did not migrate or invade were removed from 
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the top chamber using a cotton-swab. Cells attached to the bottom of the chamber were 
fixed with 100% methanol for 20 minutes, stained using 3% crystal violet in 2% ethanol 
for 20 minutes, and counted visually using an inverted microscope. Results are reported 
as the mean number of cells migrated per mm2 from triplicate determinations. Data 
reported are representative of at least three separate experiments. 
2.6 Amphiregulin Enzyme-Linked Immunosorbert Assay (ELISA) 
Pancreatic carcinoma cells (1.5-2.0 x 105) were plated in 6-well plates in complete 
culture medium overnight. The following day, cells were rinsed twice with PBS and then 
placed in serum-free medium containing 250 µg/ml BSA. For HGF-stimulation 
experiments, cells were placed in new serum free medium for 4 hours, rinsed, and then 
stimulated with HGF (10 or 50 ng/ml, as noted). After 24 hrs, conditioned medium was 
harvested, cleared by centrifugation, concentrated by centrifugation in Ambion Ultra-15 
Centrifugal filter units (Millipore), volume recorded, and AREG content analyzed by 
ELISA (Human Amphiregulin ELISA Kit, cat# ELH-AR-001, RayBiotech, Inc.) using 
recombinant human AREG as a standard. Cells were counted by hemocytometer at the 
conclusion of each experiment to confirm equal cell numbers. Data from triplicate 
determinations are reported as pg AREG/ml/105 cells with standard deviation of the 
mean. For all experiments, data presented are representative of at least three separate 
determinations. 
2.7 Whole Genome Bisulfite Sequencing (WGBS) 
Pancreatic cancer cells were grown to 70% confluence and media changed 24 
hours prior to harvest. Cells were washed with PBS, trypsinized, and collected by 
centrifugation. Whole genomic DNA was isolated using the GenElute Mammalian 
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Genomic DNA Miniprep Kit (Sigma-Aldrich). DNA quantity and quality were measured 
by a Nanodrop 2000 spectrophotometer. A minimum 260:280 ratio of 1.8 was required. 
DNA was processed for high-resolution methyl-seq by the NextGen Sequencing Core at 
the Norris Comprehensive Cancer Center. Whole genome sequencing was done on an 
Illumina NextSeq and each library was sequenced with paired-end runs for 150-bp read 
length analysis. 
2.8 Read Alignment and Differential Methylation Analysis  
Paired-end bisulfite-treated DNA reads were aligned against GRCH37 using 
Bismark [100] software version 0.14.3, permitting at most one mismatch, considering 
both sequence and bisulfite conversion mismatches. The methylation calls for each CpG 
were extracted using Bismark methylation extractor tool. Read alignment based on 
Bismark revealed that many reads could be mapped to regions in both AREG and the 
AREG pseudogene due to their high degree of homology. To allow mapping of AREG, 
the AREG pseudogene was masked during analysis, and AREG was masked when 
mapping the AREG pseudogene. As a result, some sequencing reads mapped to both the 
AREG and the AREG pseudogene, which was permitted in our analysis in Figure 4.1B 
and 4.1C only. Differential methylation analysis comparing Panc1-3D7 and Panc1-2G6 
was performed using Bioconductor DSS software version 2.10.0 [101]. The differentially 
methylated loci (DML) were determined by > 0.99 posterior probability of the difference 
in mean methylation levels being greater than 0.3. Differentially methylated regions 
(DMR) were also detected using results from the DML detection. DMLs with p-value 
less than 0.01 were chosen and joined to construct DMRs. We required DMRs to have a 
minimum length greater than 50 bps, minimum number of DML greater than 3 and 
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greater than 50% of CpG sites with significant p-value (less than 0.01). Nearby DMRs 
with distance less than 100 bps were merged into longer ones. The DMLs and DMRs 
were annotated using methylKit [102] software version 0.9.5, where we defined the 
promoters as the 1000 bp upstream and downstream of the transcription start site and the 
CpG shores as the 2000 bp flanking regions on each side of the CpG island.  
2.9 Western Blotting Analysis 
Nuclei were isolated from Panc1-2G6, Panc1-3D7 NT, and Panc1-3D7 cells 
stably expressing TDG shRNA. Cells were collected by washing 10 cm culture dishes 
with cells attached, on ice with cold PBS two times, and scraping cells with 400 l cold 
Buffer A (10 mM Hepes pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM 
DTT, 0.5 mM PMSF). Nuclei were lysed for 5 min on ice with 10% NP-40 and nuclear 
fraction collected by centrifugation. Supernatant containing cytosolic proteins were 
placed in new tubes and nuclear pellet was resuspended in cold Buffer C (20 mM Hepes 
pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1mM DTT, 1 mM PMSF). Nuclear 
extracts were centrifuged and nuclear supernatant placed in new tubes. Extracts were 
separated using 10% SDS-PAGE, transferred and immunoblotted for TDG (GeneTex, 
GT622), and Lamin A/C (EMD Millipore).  
2.10 Hydrogen Peroxide Treatment and MTT Assay  
For hydrogen peroxide treatment (Sigma-Aldrich), cells were plated in a 96-well 
plate at a density of 2000 cells per well, and four wells per condition. Medium was 
changed each day to either normal growth medium or medium containing 500 M H2O2. 
Cell density was measured each day for seven days. 20 l of 3-(4, 5-Dimethylthiazol-2-
yl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT; Fisher Scientific) were added directly 
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to cell culture media and incubated for 3 hours. Media and MTT was removed and the 
reaction stopped by adding 100 l of stop solution (90% isopropanol, 10% DMSO) to 
each well. Plates were incubated at room temperature for 20 minutes, rocking, in the 
dark, and read using a spectrophotometer at 590 nm.  
2.11 DNA Repair analysis of 6-4 Photoproducts (6-4 PP) 
Immuno-slot-blot analysis was performed as described previously [103]. Cells 
were plated in 10 cm dishes to 70% confluence. Media was removed, cells were washed 
1x with PBS, exposed to 30 J/m2 UV light and either harvested immediately or medium 
replaced. Cells were lysed (10 mM Tris pH 8.0, 1mM EDTA, 0.05% SDS, 100 g/ml 
fresh proteinase K) at indicated time points and DNA isolated. DNA was bound to a 
nitrocellulose membrane using a Bio-Dot SF microfiltration apparatus (BioRad). 
Membranes were blocked for 1 hour using 5% non-fat milk in Tris-Buffered Saline and 
Tween-20 (TBST) and probed using antibody for 6-4PP (Cosmobio) overnight. Results 
are presented as percent repair compared to the amount of initial damage (0 hr time 
point).  
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CHAPTER 3: INTEGRIN α6β4 PROMOTES INVASION OF PANCREATIC 
CANCER CELLS BY UPREGULING EGFR LIGANDS AREG AND EREG 3 
3.1 Introduction 
Integrins are essential components of tumor progression as they contribute to pro-
oncogenic properties such as survival, proliferation, and cell motility [104]. Specifically, 
integrin α6β4 is a major driver of tumor metastasis as it is critical for invasion and 
motility of cancer cells [105, 106]. Activation of integrin α6β4 results in stimulation of 
downstream signaling pathways including PI3K, MAPK, Src family kinases, Rho family 
small GTPases, and the NFAT transcription factors [25, 26, 33]. Signaling through these 
pathways contributes to properties principal to tumor progression including invasion, 
angiogenesis, anoikis-resistance, cell survival, and proliferation (reviewed in [27]). 
Previous work has found that integrin α6β4 enhances these properties in part through 
specific transcriptional upregulation of pro-tumorigenic genes, including S100A4 in 
breast cancer cell lines [30]. Furthermore, Chen et al. demonstrated that integrin α6β4 
promotes activation of the transcription factor NFAT5 thus driving S100A4 expression 
[30]. Uniquely this study was the first to reveal that integrin α6β4 could impact DNA 
methylation, as the S100A4 becomes actively demethylated within the first non-coding 
intron of the S100A4 gene in response to signaling from integrin α6β4 [30].  
This chapter will explore the impact of integrin α6β4 signaling on gene 
expression of two EGFR ligands, AREG and EREG, and examine their necessity for 
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pancreatic cancer cell migration and invasion. The importance of AREG and EREG in 
tumor progression, therapeutic resistance, and as a potential prognostic and predictive 
biomarker has been well established in multiple cancer types, including lung, ovarian, 
breast, head and neck, colon, liver, prostatic, stomach, bladder, and pancreatic cancers 
[48, 107]. Notably, EGFR signaling by AREG and EREG is enhanced in pancreatic 
carcinomas and contributes to the aggressive nature of the disease [50, 53].  
Genes that are transcriptionally silent, such as those important for development, 
are traditionally characterized as having a repressive epigenetic state that compacts 
chromatin. These repressive epigenetic marks include non-acetylated histones, lysine 
methylation at H3K27 and H3K4 and cytosine methylation at CpGs [108]. Activation of 
gene expression during cancer progression constitutes loss of these repressive marks and 
a more dynamic chromatin state that may allow for situation specific gene repression or 
activation [109]. To determine if AREG and EREG could potentially be regulated by 
epigenetic modification, I examined the promoters of AREG and EREG as well as other 
transcriptional targets of integrin α6β4 signaling. I found that large CpG rich regions 
reside in the proximal promoters of these genes, providing ideal targets for transcriptional 
regulation by DNA methylation and epigenetic modification (Fig. 3.1) Additionally, in 
gastric cancer it has been demonstrated that EREG is differentially methylated in both 
cell lines and in tumor vs. normal tissue, and this is dependent on the activities of the de 
novo DNA methyltransferase DNMT3b [110]. 
Based on these observations, I hypothesized that integrin α6β4 contributes to 
pancreatic cancer progression, in part, through transcriptional upregulation of pro-
oncogenic molecules AREG and EREG, and this is achieved through a similar 
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mechanism as S100A4 in breast cancer. I sought to test this hypothesis by utilizing well-
characterized inhibitors of epigenetic modifiers in pancreatic cancer cell lines that have 
variable integrin α6β4 expression.    
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Figure 3.1 CpG rich regions overlap with regulatory regions of genes controlled by 
integrin α6β4.  
CpG islands within the promoter regions of the sequences of genes known to be 
upregulated by integrin α6β4 were predicted using online software from the following 
websites: http://www.ebi.ac.uk/Tools/emboss/cpgplot/ and http://cpgislands.usc.edu/. 
CpG islands were defined as a DNA fragment with a GC content of more than 60%, an 
observed CpG/expected CpG ratio > 0.70, and length at least 200 base pairs. 
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3.2 Results 
3.2.1 AREG and EREG expression positively correlate with integrin α6β4  
Integrin α6β4 is associated with progression of many types of cancer in part 
through alteration of the transcriptome. Previous work in the O’Connor lab has 
demonstrated the widespread impacts of integrin α6β4 on gene transcription in both 
breast and pancreatic cancer [29, 31]. To determine if expression of AREG and EREG 
positively correlates with expression of integrin α6β4, qPCR was performed on cell lines 
with variable expression of integrin α6β4. Panc1-2G6 and Panc1-Cyt cells are derived 
from the Panc1 cell line and have very low integrin α6β4 expression or stably express a 
dominant negative form of integrin α6β4 respectively. Panc1-Cyt cells lack the 1000 
amino acid cytoplasmic signaling domain of integrinβ4 subunit, allowing the integrin to 
bind to laminin but fail in its capacity to signal [99]. Panc1-3D7 cells, also derived from 
the Panc1 cell line, AsPC1 and Suit2 cells, (listed in order of increasing expression of 
integrin α6β4) are considered high expressers, with Suit2 having more than 100-fold 
higher expression of the β4 integrin compared to Panc1-2G6. As seen in Figure 3.2A 
Panc1-2G6 and Panc1-Cyt cell lines have very low AREG and EREG expression as 
compared to Panc1-3D7, AsPC1, and Suit2, which has incredibly high AREG and EREG 
expression. Thus indicating a positive correlation between integrin α6β4 and AREG and 
EREG expression. Additionally, the contribution of integrin α6β4 to AREG and EREG in 
Panc1-3D7 cells was confirmed by stably knocking down integrin β4 using a specific 
shRNA. This knockdown resulted in a corresponding decrease in AREG and EREG 
expression (Fig. 3.2B), demonstrating the dependence of AREG and EREG on integrin 
α6β4. Lastly, to confirm that these genes correlate with integrin α6β4 expression in 
human pancreatic tumors, I analyzed the cancer genome atlas (TCGA) pancreatic ductal 
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adenocarcinoma database, which contains gene expression data as measured by whole 
transcriptome shotgun sequencing, or RNA sequencing (RNA-seq). I found that both 
AREG (Fig. 3.2C) and EREG (Fig. 3.2D) positively correlate with expression of 
integrinβ4 subunit (ITGB4) as indicated by Pearson and Spearman Coefficients > 0.3. 
These data suggest that integrin α6β4 regulates expression of AREG and EREG in 
pancreatic carcinoma cells and these data are corroborated in pancreatic cancer patient 
samples. 
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Figure 3.2. Integrin α6β4 expression positively correlates with expression of AREG 
and EREG in Pancreatic Cancer.  
(A) Expression of AREG and EREG was compared in Panc1-2G6 (low α6β4) and cells 
expressing a dominant negative α6β4 (Panc1-β4ΔCyt), Panc1-3D7, Suit2, and AsPC1 
(high α6β4) cell lines. Cells are listed in order of increasing integrin α6β4 expression. (B) 
Expression of AREG and EREG was measured following shRNA knockdown of 
integrinβ4 subunit. For these experiments RT-PCR was used to convert RNA to cDNA 
and qPCR was used to assess AREG and EREG expression. Data depicted here are 
representative of at least three different experiments and represent the mean +/- standard 
deviation. Statistical significance was calculated using a one-tailed t-test in which * 
denotes P<0.05 as compared to controls, unless otherwise indicated. (C-D) Findings were 
validated in an external dataset (TCGA), where by linear regression, gene expression 
levels of integrinβ4 subunit (ITGB4) were found to positively correlate with expression 
of AREG, EREG, in patient-derived pancreatic adenocarcinomas.  
1 2
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3.2.2 AREG and EREG are required for pancreatic cancer cell migration and invasion 
downstream of integrin α6β4  
Integrin α6β4 promotes invasion, in part, by cooperating with growth factor 
receptors such as c-Met, LPAR, RON, and EGFR [111]. Notably, c-Met and its 
associated ligand, HGF, are important players in pancreatic carcinoma and cooperation of 
c-Met with integrin α6β4 promotes invasive growth [112]. Therefore, I examined the 
individual contributions of AREG and EREG to HGF-mediated pancreatic cancer cell 
migration and invasion. While it is well established that AREG and EREG contribute to 
cancer cell metastasis [53, 113], how autocrine EGFR secretion contributes to directed 
cell motility is less well defined. Therefore, I reduced AREG and EREG expression in 
cells with high integrin α6β4 (Panc1-3D7) using target-specific shRNA and performed 
HGF-stimulated chemotaxis and chemoinvasion assays. Of note, cells that have low 
integrin α6β4 are deficient in their ability to migrate and invade, and I therefore did not 
test these cells in this study [31]. Knockdown of AREG and EREG was confirmed by 
qPCR (Fig. 3.3E, 3.3F) the day prior to chemotaxis and chemoinvasion assays. Inclusion 
in chemotaxis and chemoinvasion assays required a minimum of 90% knockdown of 
AREG or EREG. As shown in Figure 3.3, AREG or EREG knockdown results in 
decreased migration (Fig. 3.3A, 3.3B) and invasion (Fig. 3.3C, 3.3D) of Panc1-3D7 cells. 
Interestingly, effective knockdown of one ligand resulted in decreased expression of the 
other ligand by about 50%, indicating their transcriptional dependence on one another. 
These data indicate that both AREG and EREG are required for HGF-mediated migration 
and invasion of pancreatic cancer cells with upregulation of integrin α6β4.  
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Figure 3.3. AREG and EREG are both required for chemotactic migration and 
invasion of pancreatic carcinoma cells.  
AREG or EREG expression levels were reduced using lentiviral delivery of specific 
shRNAs. Upon stable selection with puromycin, cells were assessed for AREG (E) and 
EREG (F) expression by qPCR. Populations that achieved a minimum of 90% reduction 
in expression of AREG or EREG specifically were assayed for migration or invasion the 
following day (A-D). Cells (5 x 104) were placed into the top well of laminin1-coated 
Transwells for migration (A, C), or Matrigel coated wells for invasion (B, D) with either 
BSA containing DMEM (DMEM/BSA) alone or DMEM/BSA with 50 ng/ml HGF in the 
bottom well, as described in the Experimental Procedures. Cells were allowed to migrate 
for 4 hrs or invade for 6 hrs prior to harvest and quantification. Data depicted here are 
representative of at least three different experiments and represent the mean +/- standard 
deviation. Statistical significance was calculated using a one-tailed t-test in which * 
denotes P<0.05, and ** P<0.005. 
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3.2.3 NFAT5 is required for expression of AREG and EREG 
Based on the correlations between integrin α6β4 and AREG and EREG, I sought 
to explain mechanistically how integrin α6β4 regulates their gene expression. It has 
previously been established that integrin α6β4 can signal downstream to transcription 
factors, including NFAT1 and NFAT5, to promote tumor cell invasion [30, 33]. 
Considering that NFAT consensus sites are found within the AREG and EREG 
sequences, I hypothesized that these genes could be targets for the NFATs. To determine 
if AREG and EREG are regulated by NFAT5 downstream of integrin α6β4 signaling, I 
used siRNA to specifically reduce expression of NFAT5. I found that both AREG and 
EREG expression are substantially decreased with NFAT5 knockdown in Panc1-2G6 
cells (Fig. 3.4A) and even more robustly in Panc1-3D7 cells (Fig. 3.4B), as expected. 
Knockdown of NFAT5 by siRNA was confirmed by qPCR (Fig. 3.4C, 3.4D). Notably, 
knockdown of NFAT1 in pancreatic cancer cell lines did not impact expression of AREG 
and EREG (data not shown) indicating that gene regulation of AREG and EREG is 
specific for NFAT5. These data indicate that the NFAT5 transcription factor is required 
for expression of AREG and EREG in response to signaling from integrin α6β4. 
  
  34 
 
Figure 3.4. Integrin α6β4 regulates gene expression of AREG and EREG via 
NFAT5. 
Panc1 clones 2G6 and 3D7 were electroporated with siRNA specific for NFAT5 or non-
targeting control. After 72 hrs in culture, RNA was harvested from treated cells and 
assessed for AREG and EREG expression (A, B) and for knockdown efficiency of 
NFAT5 (C, D) by qPCR. Experiments depicted here are representative of at least three 
separate experiments. Data represent the mean +/- standard deviation.   
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3.2.4 AREG and EREG expression are induced by 5-Aza-CdR and this induction is 
dependent on integrin α6β4  
Prior work in the O’Connor laboratory demonstrated that integrin α6β4 
contributes to upregulation of S100A4 in breast cancer via DNA demethylation and 
suggests a similar mechanism for upregulation of AREG and EREG in pancreatic cancer 
[28, 114]. Consequently, I sought to expand these ongoing studies by defining the 
contributions of DNA methylation to AREG and EREG expression and the impact of 
integrin α6β4 in this process. To determine if AREG and EREG expression could be 
induced in response to inhibition of DNA methylation, cells with low integrin α6β4 
(Panc1-2G6) were treated with the DNA methyltransferase inhibitor, 5-Aza-CdR at either 
1M or 5 M in fresh medium daily. Cells were harvested following 3 or 5 days of 
treatment, RNA was isolated, and analyzed by qPCR. I found that both AREG and EREG 
mRNA expression increased in a time and dose dependent manner (Fig. 3.5A) 
demonstrating the susceptibility of AREG and EREG to DNA methylation [28]. In 
addition, integrin α6β4 was either required for induction of AREG and EREG mediated 
by 5-Aza-CdR, or acts in a synergistic mechanism with 5-Aza-CdR to enhance gene 
expression, as knocking down the integrin β4 subunit in Panc1-3D7 cells hindered 
epigenetic induction of AREG and EREG expression (Fig. 3.5B).  
Expanding on the finding that 5-Aza-CdR can induce AREG and EREG 
expression (Fig. 3.5A), I treated Panc1-2G6 and Panc1-Δcyt cells with 5 µM 5-Aza-CdR 
for five days to induce expression of AREG and tested the impact of integrin α6β4 on the 
process of AREG secretion. After treatment, cells were assessed for HGF-stimulated 
AREG secretion, by an ELISA on conditioned medium, and compared to the Panc1-3D7 
cells. As shown in Figure 3.5C, 5-Aza-CdR induced AREG secretion to a level 
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approximately one-quarter of that of untreated Panc-3D7 cells. However, enhanced 
section following 5-Aza-CdR indicated that the gene expression data is mirrored at the 
protein level and has the potential for propagating EGFR signaling. In addition, the level 
of AREG in the medium from unstimulated and HGF-stimulated cells differed by 20 to 
60-fold higher in Panc1-3D7 cells compared to the Panc1-Δcyt and Panc1-2G6 cells. This 
observation implicates integrin α6β4 signaling in the secretion of AREG in addition to 
regulation by DNA demethylation. 
Considering that epigenetic changes are reversible and to confirm that AREG and 
EREG DNA demethylation is an active process, cells with high expression of integrin 
α6β4, and subsequently AREG and EREG, were treated with the methyl donor for DNA 
methyltransferases SAM in fresh media daily for 3 days to a final concentration of 80 
μM. SAM is the rate-limiting molecule in the reaction facilitated by DNA 
methyltransferases. Following treatment, AsPC1 and Suit2 cells were collected and qPCR 
revealed roughly a 50% decrease in expression of AREG and EREG as seen in Figure 
3.5D. Thus indicating that AREG and EREG can be epigenetically silenced when SAM, 
the methyl donor is added to cells in excess. Taken together these data support my 
hypothesis that AREG and EREG are controlled by DNA methylation and that active 
signaling from integrin α6β4 is required to maintain an unmethylated state and drive their 
expression. 
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Figure 3.5. AREG and EREG expression is mediated by DNA demethylation in 
response to signaling from integrin α6β4.  
(A) Panc1-2G6 cells (low α6β4) were treated with vehicle only (control) or with 1 μM or 
5 μM 5-Aza-CdR in fresh medium daily for 3 or 5 days. (B) Panc1-3D7 (high α6β4) and 
Panc1-3D7 cells stably expressing an shRNA for integrinβ4 were treated with 5 M 5-
Aza-CdR as described above.  (C) Cells were incubated for 5 days with or without 5 µM 
5-Aza-CdR in fresh medium daily. Cells were then replated at 1.5 x 105 cells into 35 mm 
dishes on the fourth day. The following day, cells were serum starved for 4 hrs before 
medium was changed and HGF (0, 10 or 50 ng/ml, as noted) in serum-free medium was 
added. After 24 hrs, culture medium for each condition was assessed for AREG content 
by ELISA and cells counted to confirm equal cell numbers. Data are reported as pg of 
AREG per ml of culture medium per 1x105 cells. (D) AsPC1 and Suit2 (high α6β4) were 
treated with vehicle only (control) or 80 μM S-adenosylmethione (SAM) in fresh media 
daily, for 5 days. Data are representative of at least three different experiments. Data are 
reported as the mean of triplicate determinations +/- standard deviation.  
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3.2.5 Integrin α6β4 stably upregulates AREG and EREG through epigenetic mechanisms 
True epigenetic alterations are defined by changes that can be stably maintained 
across many cellular generations. Molecules such as 5-Aza-CdR can modify the 
epigenetic landscape, and it has been demonstrated that transient exposure to DNA 
demethylating agents can result in stable epigenomic rearrangement of select genes [115]. 
I sought to determine if transient 5-Aza-CdR treatment could recapitulate a stable 
epigenetic change in cells with low integrin α6β4. Pancreatic cancer cells were treated 
with 5-Aza-CdR at various concentrations, as indicated, for 24 or 72 hours in fresh media 
daily. 5-Aza-CdR was removed and cells were either harvested immediately or 
maintained in culture for 10 days and two passages. As seen in Figure 3.6A, expression 
of AREG and EREG when integrin α6β4 is low (Panc1-2G6), is not only induced and 
maintained in these cells following 5-Aza-CdR treatment but dramatically increases when 
kept in culture 10 days post 5-Aza-CdR removal. Cells with high integrin α6β4 (Panc1-
3D7; Fig. 3.6B) only slightly increased in transcription of AREG and EREG, as these 
stable epigenomic rearrangements may have already taken place as a result of integrin 
α6β4 signaling. Based on these data, I confirmed that integrin α6β4 contributes to the 
stable upregulation of pro-tumorigenic molecules AREG and EREG, through epigenetic 
alterations.  
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Figure 3.6. Stable epigenetic alterations are required to maintain expression of 
AREG and EREG in response to integrin α6β4  
Panc1-2G6 (A) and Panc1-3D7 (B) cells were treated with 2 μM 5-Aza-CdR for 3, or 5 
days, 5-Aza-CdR was removed and cells were either collected immediately or maintained 
in culture for 10 days. Cells were collected and RT-PCR was used to convert RNA to 
cDNA and quantitative real-time PCR was used to assess AREG and EREG expression. 
Data depicted here are representative of at least three different experiments and represent 
the mean +/- standard deviation. Statistical significance was calculated using a one-tailed 
t-test in which * denotes P<0.05 as compared to controls.  
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3.2.6 DNA methylation and not histone modifications are responsible for changes in 
AREG and EREG expression in pancreatic cancer cell lines 
DNA methyltransferase inhibitors, while specific for epigenetic changes 
associated with methylation, often impact histone methyltransferase activity as well 
[116]. Histone methylation can be activating or repressive depending on the location of 
the methylation on the histone and the methyltransferase involved [117]. Likewise, 
changes in DNA methylation can impact the ability of histone modifying enzymes to 
bind and therefore alter chromatin compaction and transcriptional status [85]. Lysine 
acetylation is the most common form of histone modification associated with gene 
expression. Since DNA is negatively charged, acetylation of histone tails reduces charge-
charge interactions between nucleosomes and DNA, and therefore opens DNA, allowing 
for transcription. Histone acetylation tends to coexist with activating marks of gene 
expression and a more “open” chromatin state, although exceptions do exist [118, 119]. 
The state of histone acetylation is dependent on the competing activity of histone acetyl 
transferases (HAT) and histone deacetylases (HDAC). While all epigenetic factors, 
including histone modifications, contribute to gene transcription, DNA methylation is 
considered the primary inhibiting factor [120]. To test the individual contributions of 
histone acetylation and DNA methylation to AREG and EREG gene expression, 
pancreatic cancer cells were treated with TSA, a histone deacetylase inhibitor, either 
alone or in combination with 5-Aza-CdR, and gene expression measured by qPCR. I 
found, as seen in Figure 3.7 that maintenance of histone acetylation alone (TSA only) 
cannot induce expression of AREG and EREG in either Panc-2G6 (Fig. 3.7A) or Panc-
3D7 (Fig.3.7B). As expected TSA in combination with 5-Aza-CdR resulted in a 
synergistic transcriptional activation of AREG and EREG in Panc1-2G6 cells, therefore 
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indicating that a repressive chromatin state is present in the absence of integrin α6β4 
signaling. Interestingly, in cells with high integrin α6β4, treatment with a histone 
deacetylase inhibitor negates the effects of 5-Aza-CdR, indicating the absence of a 
completely repressive epigenetic state.   
  42 
 
Figure 3.7. DNA methylation and not histone modifications are responsible for 
changes in amphiregulin and epiregulin expression in pancreatic cancer cell lines 
Panc1-2G6 (A) and Panc1-3D7 (B) cells were treated with either 5 μM 5-Aza-CdR 
(DAC) for 5 days, 1 μM Trichostatin A for 24 hours, or both. Cells were collected, RNA 
isolated, and gene expression of AREG and EREG measured by qPCR. Data depicted 
here are representative of at least three different experiments and represent the mean +/- 
standard deviation. Statistical significance was calculated using a one-tailed t-test in 
which * denotes P<0.05 as compared to controls 
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3.2.7 Enhancer elements drive expression of AREG and EREG 
Alterations in DNA methylation have been shown to particularly impact the 
activity of enhancers. Enhancers are elements which are responsible for activating 
specific transcriptional profiles, in part through the recruitment of transcription factors 
which in turn interact with the mediator complex [121]. Enhancers can act in cis and be 
located within or adjacent to genes or in trans and regulate gene expression as far as 
several kilobases away [121]. Enhancers have the ability to impact transcription of many 
genes or gene networks and are therefore intriguing targets for cancer therapy. To 
determine if enhancer activity is required for AREG and EREG expression in pancreatic 
cancer cells, I treated cells with JQ1, a BET bromodomain inhibitor that is specific for 
bromodomain containing protein 4 (BRD4) [122]. BRD4 interacts with the elongating 
factor P-TEFB in Pol II complexes, and is required for both protein-coding and enhancer-
derived noncoding RNAs [123]. When treating three different pancreatic cancer cell lines 
with high expression of integrin α6β4, I found that expression of AREG and EREG 
markedly decreased with low dose JQ1 treatment. These results indicate that AREG and 
EREG are transcriptionally dependent on enhancer function to maintain expression (Fig. 
3.8).  
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Figure 3.8. JQ1 treatment reduces expression of AREG and EREG 
Cells with high integrin α6β4 were treated with vehicle only (control) or 0.5 μM JQ1 
overnight and harvested for analysis by qPCR. For all experiments RT-PCR was used to 
convert RNA to cDNA and quantitative real-time PCR was used to assess AREG and 
EREG expression. Data depicted here are representative of at least three different 
experiments and represent the mean +/- standard deviation. Statistical significance was 
calculated using a one-tailed t-test in which * denotes P<0.05 as compared to controls.   
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3.3 Discussion 
Integrin α6β4 is a pro-tumorigenic molecule that directly contributes to a 
malignant phenotype through the activation of tumor-promoting genes. In this study, I 
demonstrated the dependence of the EGFR ligands, AREG and EREG, on signaling from 
integrin α6β4, and determine that the NFAT5 transcription factor and DNA 
demethylation are the driving force for their upregulation.  
The EGFR pathway is dysregulated in a variety of cancers where it contributes to 
aggressive properties of cancer cells. This pathway is a target for multiple 
chemotherapeutics either by small molecule blockade of the tyrosine kinase activity of 
EGFR, or function blocking monoclonal antibodies [124]. Unfortunately, EGFR targeted 
therapies while effective, often result in therapeutic resistance. Accordingly, 
understanding how this pathway may be regulated in a context specific manner could 
provide insight into mechanisms of tumor progression and chemotherapeutic resistance. 
In this study, I showed that integrin α6β4 positively regulates gene expression of AREG 
and EREG. In support of this finding, using the TCGA dataset on pancreatic ductal 
adenocarcinoma, I found that AREG and EREG correlated with expression of integrinβ4 
subunit, which is indicative of integrin α6β4 expression. This finding confirmed the 
physiological relevance of these studies in patients, and the impact of integrin α6β4 on 
these genes, providing mechanistic insight into aberrant regulation of the EGFR pathway 
in pancreatic cancer. 
To confirm the impact of EGFR ligands on aggressive properties of pancreatic 
cancer cells, I examined the phenotypic effects of AREG and EREG on integrin α6β4 
high expressing cells. I found that the EGFR ligands AREG and EREG are required for 
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HGF-mediated invasion and migration of pancreatic carcinoma cells. Unexpectedly, 
knockdown of each individual ligand resulted in a corresponding decrease in migration 
and invasion. This coordinated gene regulation would indicate that, while AREG and 
EREG have somewhat overlapping functions, they are not completely redundant in their 
ability to activate downstream signaling, and both seem to be necessary for these 
phenotypic effects. Notably, the contributions of AREG and EREG as pro-oncogenic 
factors in pancreatic cancer have previously been established [50, 125]. Signaling from 
AREG, specifically autocrine secretion, has been implicated in chemoresistance, evasion 
of apoptosis, self-sufficiency in growth signals, proliferation, angiogenesis, invasion and 
metastasis [48]. In fact, AREG secretion levels in pancreatic cancer patients are elevated 
to the point that this ligand has been identified as a potential biomarker, which is 
associated with a worse outcome [126]. It may be that high levels of AREG are needed 
because of its low affinity for the receptor compared to other ligands. EREG, for 
example, is found at much lower concentrations but has a broader specificity for ErbB 
receptors, and very high binding affinity, thus resulting in more potent signaling capacity 
[54]. A more comprehensive understanding of how AREG and EREG contribute to 
pancreatic cancer may provide insight into the driving mechanism of tumor invasion, 
metastasis, and chemoresistance.  
Our group [34] and others [33, 127, 128] have demonstrated that integrin α6β4 
can activate important tumor promoting transcription factors such as NFAT1, NFAT5, 
NFκB and AP-1. These factors, along with epigenetic alterations of specific genes [30], 
alter the transcriptome to facilitate an invasive phenotype. In this study, I demonstrated 
that AREG and EREG, which are established contributors of tumor progression [48, 
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107], are upregulated by the transcription factor NFAT5, as siRNA-mediated reduction of 
NFAT5 resulted in a subsequent decrease in AREG and EREG. S100A4 was the first 
identified target for NFAT5 in cancer, and S100A4 activation is mediated by integrin 
α6β4 [30]. This common mode of gene activation by integrin α6β4 implies that this may 
be a widespread manner of transcriptional activation of tumor-promoting genes in 
advanced cancers.  
This study also demonstrated the ability of DNA demethylating agents such as 5-
Aza-CdR to stably upregulate AREG and EREG. Importantly, changes in gene 
expression are also reflected by secretion of AREG, indicating that active EGFR 
signaling is likely taking place. We find that integrin α6β4 is either required for induction 
by or acting in a synergistic manner with 5-Aza-CdR as knocking down or blocking 
signaling by integrin α6β4 inhibits complete upregulation of AREG and EREG by 5-Aza-
CdR. Interestingly, in Panc1-2G6 cells long term upregulation of AREG and EREG can 
be achieved following short term 5-Aza-CdR treatment and removal, demonstrating that 
stable epigenetic modifications have taken place. Genes that are indeed epigenetically 
repressed via DNA methylation and repressive histone marks require both DNA 
demethylation and histone acetylation in order to fully achieve gene expression [120]. 
Therefore, synergistic activation of AREG and EREG in Panc1-2G6 cells using DNMT 
inhibitor in combination with HDAC inhibitor would also indicate reversal of a true 
epigenetically repressed state. This was not seen in Panc1-3D7 cells, and short-term 5-
Aza-CdR treatment and removal does not induce a high level of gene expression. Based 
on these findings I concluded that downstream of integrin α6β4 signaling, chromatin 
structure surrounding AREG and EREG shifts to a more permissive, open state allowing 
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transcription to take place. These conclusions are of importance considering that DNMT 
inhibitors such as azacitidine and decitabine are currently used chemotherapeutic agents 
for cancer, most often for the treatment myelodysplastic syndromes, acute myeloid 
leukemia and chronic myelomonocytic leukemia [129]. However, only about 50% of 
hematological patients show a positive response. Likewise, a variety of clinical trials in 
solid tumors only showed a positive response rate for 3-35% of patients treated either 
alone or in combination with epigenetic therapies [130]. These low success rates are in 
part due to the nonspecific nature of these drugs and unexpected activation of tumor 
promoting genes such as AREG and EREG. Identification of molecules contributing to 
epigenetic upregulation, such as integrin α6β4 may help better predict patient response.  
Interestingly, this study expands on others that have examined the impact of the 
tumor microenvironment on epigenetic regulation.  Work in squamous cell carcinoma 
and MDA-MB-231 breast cancer cells demonstrated that ECM content, cell-cell 
interactions, and 3D environment impact the methylation state of the E-cadherin 
promoter and this dynamic epigenetic plasticity helps drive EMT [131, 132]. These 
observations collectively solidify the role of the tumor microenvironment in regulating 
DNA methylation. Considering that signaling through integrin α6β4 is activated during 
and contributes to metastasis, the context dependent, dynamic DNA demethylation of 
pro-oncogenic molecules downstream of integrin α6β4 could be a major contributing 
mechanism to advanced carcinomas. Thus placing the tumor microenvironment at a 
unique nexus between the metastatic phenotype and tumor epigenetics. By understanding 
how tumor promoting molecules such as integrin α6β4 cooperate with epigenetic drugs 
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and target other pro-oncogenic molecules for DNA demethylation we may be able more 
effectively use these therapies, specifically in the case of advanced stage metastasis.  
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CHAPTER 4: INTEGRIN α6β4 ALTERS GENE SPECIFIC AND GENOME 
WIDE DEMETHYLATION PATTERNS 
4.1 Introduction 
Appropriate DNA methylation patterns are crucial for establishment and 
maintenance of gene expression in normal functioning tissues. Abnormal DNA 
methylation patterns are both found in and contribute to the development of cancer and 
progression to metastatic disease. Additionally, studies done examining methylation 
patterns from normal and diseased tissues have led to the hypothesis that DNA 
methylation events prior to mutations are the driving force in tumor development. An 
established understanding of how the epigenome contributes to cancer is critical for the 
future of effective cancer therapies. 
4.1.1 Genome Wide changes in DNA Methylation and Metastasis 
Cancer cell invasion and metastatic disease is ultimately what leads to death of 
patients, as genetic and epigenetic changes have taken place between primary tumor and 
secondary sites. Additionally, the systemic nature of metastases makes treatment difficult 
and resistance to chemotherapeutic agents very common [133]. The metastatic cascade is 
characterized by invasion of tumor cells from the primary site through the basement 
membrane and stroma, intravasation into the lymphatic or blood vessel system, survival 
during transport, extravasation to a secondary site, survival in the new environment, and 
reestablishment of proliferation [133]. Each step in this process is rate limiting and 
reorganization of the chromatin to alter transcriptional profiles is necessary to adjust 
expression of genes required for this process [61].  
Investigations in breast cancer of metastatic-specific alterations in DNA 
methylation, have revealed unique methylation patterns in breast cancer subtypes and 
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when comparing metastatic vs. primary tumors [61, 134]. Fang et al. identified a panel of 
genes that were differentially methylated in breast cancer, or a breast CpG island 
methylator phenotype (B-CIMP). The presence of B-CIMP was characteristic of tumor 
metastatic potential, prognosis, and survival, and therefore provides a potential biomarker 
and prognostic factor for metastatic disease. Similarly, work in gastric cancer has shown 
that specific epigenetic alterations in a panel of genes can predict metastasis and overall 
patient survival [135]. Integrin α6β4 is a major contributor to metastasis as it senses and 
coordinates cellular response to the tumor microenvironment. This includes enhanced 
cellular proliferation, directly promoting filapodia and lamellipodia formation to drive 
cell motility, upregulation of the MMPs that break down ECM and activate pro-proteins 
such as AREG and EREG, activation of pro-oncogenic signaling networks, and 
transcriptional activation of a variety of oncogenes [11, 25, 136-141]. My study 
examined the impact of integrin α6β4 on DNA methylation, as identifying critical 
components of this process provide insight into how pro-metastatic molecules become 
upregulated during tumor progression.  
4.1.2 DNA Methylation of Enhancers 
Enhancers are transcriptional elements that promote gene activation by acting as a 
hub for multiple transcription factors to interact with the mediator complex and in turn 
recruit RNA polymerase II [142]. Additionally, a single enhancer can impact expression 
of multiple genes or gene clusters, and many enhancers can act on a single gene 
depending on the context [143]. However, unlike promoters, enhancers are independent 
of orientation or location, as they can be found long distances from the TSS, downstream 
of promoters, and within introns [121]. Of the known transcriptional elements, enhancers 
are the most dynamic [144]. Heintzman et al. showed that enhancers impact cell-type and 
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context specific gene expression patterns and could therefore be critical for cancer type 
specific, or even metastasis specific transcriptional patterns [144]. Importantly, 
establishing how enhancer specific activation is achieved is critical for understanding and 
targeting key epigenetic components in cancer progression.  
One mechanism that impacts the ability of enhancers to function is DNA 
methylation. Contrary to the preceding dogma, work done by Young and colleagues 
demonstrated that DNA methylation of enhancers correlates better with transcription of 
associated genes than do promoters [145]. Additionally, DNA methylation of enhancer 
elements is more dynamic, allowing for situation and context specific alterations in 
methylation and their associated gene expression changes. My study identified alterations 
in DNA methylation mediated by integrin α6β4, in association with potential enhancer 
elements.   
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4.2 Results 
4.2.1 Integrin α6β4 promotes loci specific DNA demethylation at enhancer elements of 
AREG and EREG  
To define DNA demethylation changes that drive expression of AREG and EREG 
in response to integrin α6β4 signaling, genomic DNA was isolated from pancreatic 
cancer cells with either high (Panc1-3D7) or low (Panc1-2G6) integrin α6β4 expression. 
DNA was exposed to sodium bisulfite conversion followed by high-resolution next-
generation whole genome sequencing (WGBS). Alignment to the reference genome was 
achieved using Bismark, a methylation caller and aligner specific for Bisulfite 
Sequencing projects. As illustrated, cells with high integrin α6β4 (Fig. 4.1A and 4.1B; 
bottom panels) have reduced DNA methylation within intronic regions of both EREG 
(Fig. 4.1A) and AREG (Fig 4.1B), confirming my hypothesis that integrin α6β4 drives 
site-specific DNA demethylation within these genes. Importantly, we also found 
differentially methylated loci in an AREG pseudogene, which lies directly downstream of 
AREG (Fig. 4.1C). When comparing AREG and AREG pseudogene, as seen in Figure 
4.1B and 4.1C, both the sequence structure similarity as well as the potential for 
regulatory similarity are noted. The sequences of AREG and AREG pseudogene are 
nearly identical, achieving 99% homology when blasted against the reference genome 
(GRCH37). Since Bismark only reports unique matches during the mapping step, the 
multi-mapping scenario of AREG and its pseudogene made it difficult to investigate the 
methylation alternations in these two regions. The analysis was possible by masking 
AREG pseudogene and mapping AREG, and vice-versa for AREG pseudogene. I 
attempted to investigate this further by using bisulfite conversion with methylation 
specific PCR to confirm altered CpGs within this region. However, the sequence 
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similarity between these two regions and difficulty designing unique primers for bisulfite 
converted DNA made this analysis technically not feasible. 
A super-enhancer lies between AREG and the AREG pseudogene [145] within 
the range capable of impacting transcription of both AREG and EREG. Considering that 
AREG and EREG expression is robustly decreased in response to JQ1 treatment, we 
examined DNA methylation of this super-enhancer. We found no significant differences 
in super-enhancer DNA methylation (data not shown), indicating that it is unlikely that 
DNA methylation of this element is the major driver for enhanced AREG and EREG 
gene expression. However, more extensive investigations of this region would be 
required to confirm that the super-enhancer is not critical for AREG and EREG 
expression in response to signaling from integrin α6β4. 
Interestingly, regions that have the greatest differences in DNA methylation in 
both AREG and EREG as a result of integrin α6β4 signaling corresponded to areas 
enriched in H3K27Ac marks (Fig 4.1A, 4.1B), as annotated in the UCSC genome 
browser. H3K27Ac has been shown to correspond to active enhancer elements in the 
genome [146]. While the analysis examining H3K27Ac is not specific for our chosen cell 
type, it does mark potential sites for regulation by enhancers, and very tightly associates 
with changes in DNA methylation. Taken together, these data, along with the observation 
that BRD4 is required for AREG and EREG expression, suggest that DNA methylation 
of an enhancer element localized within the proximal promoters of AREG and EREG are 
driving their expression in response to signaling from integrin α6β4 in pancreatic cancer 
cell lines. A more in depth analysis of these regulatory regions will need to be performed 
to confirm this hypothesis.   
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Figure 4.1 Loci specific changes in DNA methylation in AREG and EREG genes 
downstream of integrin α6β4 signaling 
(A-C) Genomic DNA from Panc1-2G6 (β4 low; upper panels) and Panc1-3D7 (high β4; 
lower panels) was processed for high-resolution methyl-seq by the NextGen Sequencing 
Core at the Norris Comprehensive Cancer Center. Samples were analyzed 
bioinformatically and percent methylation shown for EREG (A), AREG (B), and the 
AREG pseudogene (C). 
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4.2.2 Integrin α6β4 contributes to genome-wide DNA demethylation 
In addition to investigating targeted effects of integrin α6β4 on DNA methylation, 
we examined genome-wide effects using the data generated by WGBS on the Illumina 
NextSeq. A total of 236,371 Differentially Methylated Loci (DML) (207,168 
hypomethylated and 29,203 hypermethylated) were identified comparing Panc1-3D7 vs. 
Panc1-2G6. Figure 4.2A illustrates the percentage of hypermethylated and 
hypomethylated events per chromosome as a percent of the number of DMLs. Of the 
DMLs that were identified, 87.6% were hypomethylated and 12.4% were 
hypermethylated, thus indicating that integrin α6β4 dramatically shifts chromatin to a 
more hypomethylated state.  
More detailed analysis of these data revealed that only 3.1% of these loci were 
located in promoter regions, 2.1% in exonic regions, 31.1% in intronic regions and 63.1% 
were in intergenic regions, or regions that have otherwise not been classified as mapped 
to reference genome GRCH37 (Fig 4.2B). A total of 13,889 differentially methylated 
regions (DMR) were identified. Among them, only about 4% were located in CpG 
islands, and 5% in CpG shores (Fig. 4.2C). Additionally, when comparing all cytosines 
located at CpG sites in the genome, the Panc1-3D7 cells had roughly 12% more 
demethylated loci than integrin α6β4 low cells.   
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Figure 4.2 Distribution of differentially methylated loci and regions in response to 
signaling from integrin α6β4  
(A) Percent hypomethylation (gray) and hypermethylation (black) per chromosome when 
comparing Panc1-3D7 vs. Panc1-2G6. E) Location of DMLs across the genome. F) 
Percent of DMRs located in CpG islands and shores. 
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4.2.3 Integrin α6β4 signaling dramatically impacts global enhancer methylation 
The data thus far suggests that AREG and EREG are regulated by DNA 
demethylation of enhancer elements. Therefore, we examined alterations in DNA 
methylation patterns that correspond to H3K27Ac genome-wide, a mark of active 
enhancers. We found that 40,609 CpGs associated with H3K27Ac were hypomethylated 
as opposed to only 13,679 CpGs hypermethylated (Fig 4.3A). These events correspond to 
4930 genes that have alterations in methylation within enhancer elements (Fig 4.3A). As 
seen in Figure 4.3B, the majority of these altered DML are localized to intronic and 
intergenic regions. This observation is typical of enhancer elements, as most enhancers 
are part of non-coding regions of the genome [147].   
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Figure 4.3 Integrin α6β4 promotes hypomethylation at potential enhancer elements  
(A) Panc1-3D7 (high integrin α6β4) were compared to Panc1-2G6 (low integrin α6β4) 
cell lines and changes in DNA methylation graphed (left bar). Hypermethylated loci are 
indicated in black and hypomethylation in grey. DML that aligned with potential 
H3K27Ac sites are indicated by the right bar and represent 23% of all DMLs, 
representing 4930 genes. (B) All DML that mapped to H3K27Ac sites were identified 
and location characterized.  
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4.2.4 Global DNA demethylation by integrin α6β4 requires DNA repair 
To determine if the DNA methylation changes found in pancreatic cancer cells 
were consistent in other models for integrin α6β4 signaling, the triple negative breast 
cancer cell line BT549 was used to analyze DNA methylation changes in response to 
integrin α6β4 signaling. The parental cell line and BT549 stably expressing a non-
targeting shRNA construct were used as the control integrin α6β4 null cells. In the 
experimental samples the integrin β4 subunit was stably transfected into BT549 cells and 
a colony chosen, or a pooled population that overexpresses integrin α6β4. Of note, 
BT549 cells lack integrin α6β4 and when the integrin β4 subunit is stably transfected, 
cells gain an enhanced ability to migrate, invade, and proliferate (data not shown). When 
comparing integrin α6β4 high vs. integrin α6β4 low cells we saw very similar results as 
compared to the pancreatic cancer cell lines. Roughly 250,000 CpGs were altered in 
response to integrin α6β4 expression, of which 90% were hypomethylated and 10% were 
hypermethylated (Fig 4.4, middle bar); thus indicating that integrin α6β4 globally impacts 
DNA methylation levels, shifting the genome to a hypomethylated state, in multiple 
models of cancer.  
A third model was chosen to examine integrin α6β4 signaling on DNA 
methylation, a triple negative breast cancer cell line lacking integrin α6β4, Hs578T. Of 
note, transfection with the integrin β4 subunit in to Hs578T cells does not confer an 
enhanced ability to invade, as seen with the other two models. The currently accepted 
mechanism for how active DNA demethylation is achieved is through enzymatic removal 
by DNA repair proteins. Hs578T cells are deficient in their ability to repair DNA 
damage. When examining whole genome DNA methylation following stable 
overexpression of integrin α6β4, there were very few alterations in DNA methylation 
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patterns (Fig 4.4, right bar) via hyper or hypomethylation. This would indicate that DNA 
repair is required for alterations in DNA methylation mediated by integrin α6β4. This 
concept will be explored further in the following chapter.   
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Figure 4.4 Integrin α6β4 promotes DNA demethylation in Breast and Pancreatic 
Cancer Cell lines  
Genomic DNA was isolated from pancreatic cancer cell lines (Panc1) and triple negative 
breast cancer cell lines (BT549, Hs578T). Hs578T cells are deficient in their ability to 
repair damaged DNA. Whole genome bisulfite sequencing was performed on all cell 
lines and DNA methylation levels compared in integrin α6β4 high vs. integrin α6β4 low 
cells. Black bars represent number of differentially methylated hypermethylation events, 
and green bares represented hypomethylated events.  
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4.3 Discussion 
The analysis of genome-wide DNA methylation patterns revealed that integrin 
α6β4 dramatically reshapes the epigenetic landscape, shifting global DNA methylation 
patterns to a more hypomethylated state. Interestingly, studies in breast cancer revealed 
that genome-wide alterations in DNA methylation occur surprisingly early on in cancer 
progression and may act as a driver of tumorigenesis [148]. My study proposes an 
additional shift in DNA methylation patterns from a benign to a malignant state, when 
integrin α6β4 is activated. Similarly, during cancer cell invasion, Herman and colleagues 
found that the E-Cadherin promoter is differentially methylated [132]. Additionally, 
Lujambio et al found that methylation of a large number of microRNAs specifically 
contributes to metastasis by altering expression of oncogenic target genes [149].  These 
studies support my hypothesis that a specific epigenetic signature is associated with and 
promotes invasive cancer growth. Importantly, specific epigenetic signatures could be 
used to as a diagnostic marker of metastatic disease and a potential target for therapies.  
Furthermore, this study confirms that changes in specific CpG methylation within 
the AREG and EREG genes occur in intronic regions that are not defined by the presence 
of CpG islands. These sites of altered DNA demethylation corresponded to known sites 
of H3K27Ac as identified by the ENCODE project in the UCSC genome browser. My 
data demonstrating that AREG and EREG expression is highly dependent on BRD4 
activity, suggests that enhancer elements are necessary to drive gene expression. In 
support of this concept, previous work on S100A4 yielded similar results as specific 
changes that control gene expression reside in an enhancer element located in a CpG rich 
region rather than a CpG island [114]. Similar to our gene specific data, the majority of 
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hypomethylation events induced by integrin α6β4 are not localized to CpG islands or 
promoter regions; but were instead found in intronic and intergenic elements. In addition, 
23% of these regions corresponded to potential sites of H3K27ac, which is indicative of 
enhancer location [146]. These data provide evidence that integrin α6β4 is impacting 
methylation of regulatory elements as opposed to direct activation through demethylation 
of promoters. These changes in DNA methylation are not surprising as hypomethylation 
of enhancer elements is tightly linked to overexpression of cancer promoting genes and 
gene profiles, when compared to promoter methylation [150, 151]. Additionally, studies 
have shown that tissue specific intergenic CpG island methylation correlates with sites of 
alternative promoters imbedded within genes [152]. Therefore, these data suggest that 
this shift in methylation patterns mediated by integrin α6β4 is indeed a mechanism 
driving gene expression and progression to a more malignant phenotype in pancreatic 
cancer cells. While other evidence exists to suggest that the tumor microenvironment can 
influence epigenetics [131, 153, 154], this study is the first to identify a specific mediator 
of the microenvironment, integrin α6β4, as a regulator of this process.  
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CHAPTER 5: AREG AND EREG EXPRESSION REQUIRE BASE EXCISION 
REPAIR DOWNSTREAM OF INTEGRIN α6β4 
5.1 Introduction 
Genes that are transcriptionally silent, such as those important for development, 
are traditionally characterized as having a repressive epigenetic state that compacts 
chromatin. These repressive epigenetic marks include non-acetylated histones, lysine 
methylation at H3K27 and H3K4 and cytosine methylation at CpGs [108]. Activation of 
gene expression during cancer progression constitutes loss of these repressive marks and 
a more dynamic chromatin state that may allow for situation specific gene repression or 
activation. Specifically, removal of the repressive methyl group at 5-mC, or DNA 
demethylation, is required for activation of gene expression. 
5.1.1. DNA Demethylation 
DNA demethylation can occur through a passive or an active process. Passive 
removal occurs spontaneously over several rounds of replication as a result of loss or 
mistakes by the primary maintenance methyltransferase, DNA methyltransferase 1 
(DNMT1) [155]. Spontaneous DNA demethylation results in stochastic changes 
eventually diluting out the methyl groups through rounds of replication. Active DNA 
demethylation is more tightly regulated and proceeds through either direct removal of the 
methyl group by a DNA demethylase or indirect enzymatic removal by the Ten-Eleven 
Translocation methylcytosine dioxygenase (TET) proteins and DNA repair. However, 
strong evidence for a vertebrate DNA demethylase does not currently exist, and a 
mechanism for targeting by direct removal has not been identified. Moreover, the C-C 
bond found in 5-mC is difficult to break energetically, making active direct DNA 
demethylation unlikely [156]. Active indirect removal is the more probable mechanism 
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involved in upregulation of pro-tumorigenic genes. Importantly, two different DNA 
repair pathways have been implicated in active DNA demethylation, BER and NER [157, 
158]. These pathways have partially overlapping functions in terms of damage repair and 
DNA demethylation. Consequently, it is still unknown under what conditions each 
pathway becomes activated to target specific CpG sites for DNA demethylation.  
5.1.2. DNA Demethylation by Base Excision Repair 
My study focused on DNA demethylation mediated by the BER pathway, which 
is described in detail below. Modification of 5-mC by TET has been identified as a 
crucial step in DNA demethylation as this protein recognizes specific 5-mC to be targeted 
for removal by DNA repair and conversion from 5-mC to 5-hydroxymethyl cytosine (5-
hmC) [159]. 5-hmC can be further oxidized by the TET proteins to produce 5-
carboxylcytosine (5-caC) and 5-formylcytosine (5-fC). These derivatives are found less 
often in the genome and while their complete function is still being characterized, it is 
clear that these modifications are playing a critical role in epigenetic regulation [160].  
5-hmC and other oxidized 5-mC products are subsequently identified by the 
protein growth arrest and DNA damage inducible protein alpha (GADD45A). GADD45A 
activity impacts multiple cellular functions including cell cycle, apoptosis, cellular stress 
response, and most recently DNA demethylation [161]. Figure 5.1 summarizes how 
enzymatic, active DNA demethylation mediated by GADD45A is achieved based on my 
understanding of the current literature. GADD45A is responsible for recruitment of other 
repair factors to CpG sites for removal of methyl groups, and has been implicated as a 
necessary step in DNA demethylation by DNA repair as it provides the link between 
epigenetics and DNA repair [162, 163]. GADD45A can in turn recruit activation induced 
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cytidine deaminases such as the AID and APOBEC proteins [163]. AID is responsible for 
deaminating 5-hmC to 5-hydroxymethyl Uracil (5-hmU), in the process generating a G-U 
mismatch. This mismatch is identified and subsequently cleaved and removed by the 
DNA glycosylase, TDG. Methyl-binding protein 4 (MBD4) is also a DNA glycosylase 
that can contribute to active DNA demethylation. However, MBD4 does not require the 
activity of GADD45A or AID and can directly act on TET created derivatives of 5-mC. 
Notably, it has been demonstrated that GADD45A mediated DNA demethylation is 
dependent on TDG, as they occur in complex together where DNA demethylation is 
actively taking place [164]. This cleavage activates the normal functions of the BER 
pathway including cleavage of the DNA backbone by AP-endonuclease (APE1) and 
repair back to a non-methylated cytosine by X-ray Repair Cross Complementing Protein 
(XRCC1), Poly-ADP Ribose Polymerase (PARP1), DNA ligase, and DNA polymerase. 
Therefore, considering that AREG and EREG are activated by DNA demethylation, I 
chose to investigate the influence of DNA repair on transcription of AREG and EREG 
downstream of integrin α6β4.    
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Figure 5.1 GADD45A mediated DNA demethylation by Base Excision Repair 
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5.2 Results 
5.2.1 DNA repair is required for transcription of AREG and EREG 
Gemcitabine is a currently used chemotherapeutic that has multiple proposed 
mechanisms of action, one of which is inhibition of ribonucleotide reductase. This 
inhibition causes depletion of deoxynucleotide triphosphates necessary for DNA 
synthesis, and completion of DNA repair [165]. Interestingly, Gemcitabine has been 
shown to specifically inhibit GADD45A mediated gene activation via DNA 
demethylation and DNA repair [166]. Therefore, to investigate the role of GADD45A 
mediated DNA repair in expression of AREG and EREG, Panc1-2G6 and Panc1-3D7 
cells were treated with 10 μM gemcitabine for 72 hours and their RNA harvested for 
qPCR. As demonstrated in Figure 5.2, AREG and EREG expression decreases by 63% 
and 90% respectively in cells with high integrin α6β4 in response to gemcitabine 
treatment. These data indicate that a functioning DNA repair pathway, possibly mediated 
by GADD45A is required to maintain expression of AREG and EREG.    
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Figure 5.2 DNA repair is required for expression of AREG and EREG in integrin 
α6β4 high expressing cells 
Panc1-2G6 and Panc1-3D7 cells were treated for 72 hours with 10 μM gemcitabine. 
RNA was isolated and gene expression of AREG and EREG determined by qPCR. Data 
depicted here are representative of at least three different experiments and represent the 
mean +/- standard deviation. Statistical significance was calculated using a one-tailed t-
test in which * denotes P<0.05 as compared to controls 
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5.2.2 GADD45A is the rate-limiting molecule in upregulation of AREG and EREG 
GADD45A has been demonstrated to be the recognition step for DNA 
demethylation by both NER and BER, and is found in complex with molecules from each 
pathway [162, 164]. Therefore, to confirm the contribution of this molecule to AREG and 
EREG expression, I specifically modulated GADD45A in pancreatic cancer cells. I 
reduced GADD45A expression in pancreatic cancer cells by using siRNA to knockdown 
or overexpressed GADD45A by adenoviral infection. Efficient knockdown or 
overexpression was confirmed by qPCR (Fig. 5.3C, F). As seen in Fig. 5.3A & 5.3B, 
knockdown of GADD45A resulted in decreased expression of AREG and EREG in cells 
with both integrin α6β4 low and high expression. Similarly, overexpression of 
GADD45A resulted in a further increase in AREG and EREG expression, only when 
integrin α6β4 is high (Fig 5.4D, E). Taken together these data indicated that GADD45A 
is a rate-limiting step in gene activation of AREG and EREG and requires integrin α6β4, 
as induction was not achieved in Panc1-2G6 cells. Based on these data, I concluded that 
GADD45A mediated DNA demethylation proceeds through the BER pathway in my 
system and tested this hypothesis further.   
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Figure 5.3 GADD45A is necessary and required for expression of AREG and EREG 
Changes in AREG and EREG expression downstream of overexpression or knockdown 
of GADD45A were measured by qPCR in Panc1-2G6 (A & D) and Panc1-3D7 (B & E). 
Transient knockdown of GADD45A was achieved using electroporation and specific 
siRNA (C). Adenovirus was used to overexpress GADD45A in Panc1-2G6 and Panc1-
3D7 cells (F). Data depicted here are representative of at least three different experiments 
and represent the mean +/- standard deviation. Statistical significance was calculated 
using a one-tailed t-test in which * denotes P<0.05 as compared to controls   
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5.2.3 TET1 mediates DNA demethylation of AREG and EREG 
Discovery of TET proteins allowed for a possible mechanism for active DNA 
demethylation, as the TETs are solely responsible for conversion of 5-mC to 5-hmC, 5-fC 
and 5-caC in mammalian DNA [167]. 5-hmC is the key component for active DNA 
demethylation by DNA repair, as it provides a substrate for further processing to a 
cytosine by the DNA glycosylases and BER. Three TET proteins have currently been 
identified with enzymatic activity for 5-mC. Therefore, using specific shRNAs, I depleted 
TET1 in cells with high integrin α6β4 expression (Fig. 5.4A). As demonstrated in Figure 
5.4B, AREG and EREG expression is robustly decreased following a 70% reduction in 
TET1.  
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Figure 5.4 TET1 is required for expression of AREG and EREG  
(A) Transient knockdown of TET1 was achieved using lentiviral infection, followed by 
puromycin selection in Panc1-3D7 cells, and reduced expression confirmed by qPCR. (B) 
Changes in AREG and EREG expression were measured by qPCR. Data depicted here 
are representative of at least three different experiments and represent the mean +/- 
standard deviation. Statistical significance was calculated using a one-tailed t-test in 
which * denotes P<0.05 as compared to controls.  
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5.2.4 Integrin α6β4 enhances nuclear localization of TDG to promote DNA 
demethylation 
DNA glycosylases TDG and MBD4 have both been implicated as required 
molecules for active DNA demethylation by DNA repair, in different contexts. 
Specifically, TDG has been found in complex with AID and GADD45A during the 
process of active DNA demethylation [157]. Furthermore, genome-wide analysis reveals 
that depletion of TDG results in accumulation of TET induced 5-mC derivatives [168]. 
MBD4 is unique in that it can directly excise 5-hmC without the assistance of other 
molecules such as GADD45A [169, 170]. Therefore, I stably knocked down either 
MBD4 or TDG to assess the contributions of known DNA glycosylases to AREG and 
EREG expression. Figure 5.5A, demonstrates that stable knockdown of TDG is achieved 
in Panc1-3D7 cells, as visualized by nuclear fractionation and western blot analysis. 
Additionally, it can also be appreciated in Figure 5.5A that there is much higher nuclear 
expression of TDG when integrin α6β4 is high as compared to low expressing cells 
(Panc1-2G6). This would indicate that integrin α6β4 causes preferential nuclear 
localization of TDG, potentially for enhanced DNA demethylation or DNA repair, which 
will need to be investigated further. As seen in Figure 5.5B, this stable knockdown of 
TDG resulted in marked downregulation of AREG and EREG in integrin α6β4 high 
expressing cells, indicating that TDG is necessary to maintain expression of these genes 
when integrin α6β4 is upregulated. Interestingly, knockdown of MBD4 in both Panc1-
2G6 (Fig. 5.5C) and Panc1-3D7 (Fig 5.5E) cells had no effect on expression of AREG 
and EREG (Fig. 5.5 D & 5.5F); thus indicating that DNA demethylation of AREG and 
EREG is specific for TDG mediated DNA repair.    
  76 
 
Figure 5.5 TDG is preferentially expressed in the nucleus downstream of integrin 
α6β4 and is necessary and specific for AREG and EREG expression 
Stable knockdown of TDG (A) and MBD4 (C & E) was achieved using lentiviral 
infection, followed by puromycin selection in Panc1-2G6 cells for MBD4 and Panc1-3D7 
cells for TDG and MBD4, and reduced expression confirmed. Western blot was used to 
examine nuclear protein levels of TDG in Panc1-2G6 cells, and Panc1-3D7 cells stably 
expressing a NT vector or TDG shRNA. Changes in AREG and EREG expression were 
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measured by qPCR following stable knockdown of TDG (B) and MBD4 (D & F). Data 
depicted here are representative of at least three different experiments and represent the 
mean +/- standard deviation. Statistical significance was calculated using a one-tailed t-
test in which * denotes P<0.05 as compared to controls. 
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5.2.5 PARP-1 is a mediator of integrin α6β4 upregulation of AREG and EREG 
PARP-1, a required molecule for BER has been shown to modulate chromatin 
patterns including DNA methylation [171]. PARP-1 has been implicated in genome-wide 
and locus specific active DNA demethylation in part through epigenetic regulation of 
TET1 [172]. Using a PARP-1 inhibitor, DPQ, I saw a dramatic decrease in AREG and 
EREG expression in high integrin α6β4 expressing cells (Panc1-3D7; Fig. 5.6B).  
However, in cells with low integrin α6β4, expression of AREG and EREG was relatively 
unaffected by PARP-1 inhibition (Fig. 5.6A), indicating that PARP-1 is a mediator of 
AREG and EREG transcriptional induction regulated by integrin α6β4.  
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Figure 5.6 PARP-1 activity regulates AREG and EREG expression mediated by 
integrin α6β4  
Panc1-2G6 (A) and Panc1-3D7 (B) cells were treated with 1 or 10uM DPQ for three days 
to inhibit PARP-1 function. Gene expression of AREG and EREG were measured by 
qPCR. Data depicted here are representative of at least three different experiments and 
represent the mean +/- standard deviation. Statistical significance was calculated using a 
one-tailed t-test in which * denotes P<0.05 as compared to controls.  
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5.2.6 NER is not required for expression of AREG and EREG 
Since my data indicate that AREG and EREG DNA demethylation is an active 
process, and considering that both BER and NER have been implicated as mediators of 
DNA demethylation, I chose to examine the NER pathway. The NER pathway, including 
the Xeroderma Pigmentosum proteins, XPA, XPG, and XPF, have been implicated in 
active DNA demethylation by DNA repair [158, 173]. To test if NER is required to 
maintain AREG and EREG expression, I targeted molecules critical for and specific to 
the NER pathway and examined their impact on AREG and EREG expression. I 
hypothesized that manipulation of NER proteins would not impact AREG and EREG 
expression, as NER is responsible for repairing helix-distorting lesions on a stretch of 
DNA. This is different from BER, which repairs single nucleotide mismatches.  
XPA is a critical component of the NER system as it is recruited to sites of DNA 
damage where it allows for appropriate assembly of the NER machinery specifically 
proteins required for incision [174]. When knockdown of XPA (Fig. 5.7A) was achieved, 
transcription of AREG and EREG in both Panc-2G6 (low α6β4; Fig. 5.7B) and Panc-3D7 
(high α6β4; Fig. 5.7C) remained unaffected. Additionally, XPG and XPF are both crucial 
for completion of NER as they are responsible for incision at the junction of single and 
double stranded DNA at the 5’ and 3’ ends, respectively, allowing for subsequent 
removal of the DNA fragment containing the helix distorting lesion [175, 176]. 
Interestingly, XPF and XPG have the ability to promote gene expression through 
chromatin looping and DNA demethylation [173]. I hypothesized that if NER were 
critical for AREG and EREG expression, then completion of this incision process would 
be vital for the complete removal of repressive methyl marks. Using specific shRNAs I 
knocked down the Excision Repair Cross Complementation Group 4 (ERCC4) gene 
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(XPF protein; Fig. 5.7D) and ERCC5 (XPG; Fig. 5.7G) in pancreatic cancer cell lines, 
and demonstrated that effective knockdown of NER genes had relatively little or no 
effect on AREG and EREG expression (Fig 5.7E-F, I-J). Taken together these data 
indicate that NER is not required to maintain expression of AREG or EREG, regardless 
of expression of integrin α6β4. Therefore, I concluded that integrin α6β4 promotes gene 
specific upregulation of AREG and EREG through a BER mediated process.  
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Figure 5.7 NER is not required for expression of AREG and EREG 
Using lentiviral transfection stable knockdown of XPA (A), ERCC4 (D), and ERCC5 (G) 
was achieved in Panc1-2G6 (low α6β4) and Panc1-3D7 (high α6β4) cells as confirmed 
by qPCR. AREG and EREG expression was examined following knockdown in cells with 
both low α6β4 (B, E, H) and high α6β4 (C, F, J) expression. Data depicted are 
representative of at least three different experiments and represent the mean +/- standard 
deviation.   
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5.2.7 Integrin α6β4 promotes DNA repair of oxidative stress and UV-induced DNA 
damage 
The data to this point indicates that integrin α6β4 utilizes DNA repair 
mechanisms to maintain a hypomethylated state in the AREG and EREG promoters. I 
rationalized that if integrin α6β4 is using the BER pathway to activate specific genes, 
integrin α6β4 may also enhance DNA repair in response to DNA damage. Accordingly, I 
induced oxidative damage, which would subsequently be repaired by the BER pathway, 
by exposing cells to 500 M H2O2 over seven days and measured the number of viable 
cells each day via MTT assay. I observed a modest decrease in cell number with high 
integrin α6β4 (Panc1-3D7); however, increase in cell number was nearly abolished in 
cells with low integrin α6β4 (Panc1-2G6) in response to H2O2 treatment. This lack of 
cellular proliferation in response to H2O2 treatment indicated a decreased ability to 
survive and tolerate insult induced by oxidative stress (Fig 5.8A). To measure DNA 
repair more directly, and to synchronize the repair process, I examined NER dependent 
DNA repair by exposing cells to 30 J/m2 UV light and measuring resolution of 6-4 
photoproducts over time. As illustrated in Figure 5.8B, cells with high integrin α6β4 
resolve UV induced lesions more rapidly than cells with low integrin α6β4, with a 
difference in half-life of about 1 hour. Taken together, this indicates that integrin α6β4 
can both utilize DNA repair, and enhance the ability of cells to respond to, repair, and 
survive in the presence of DNA damage.   
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Figure 5.8 Integrin α6β4 promotes DNA repair and cell survival in response to DNA 
damage 
(A) Cells were treated with 500 M H2O2 in fresh media daily for 7 days. Each day cell 
proliferation was measured by MTT colorimetric assay. (B) Cells were exposed to 30 
J/m2 UV light and DNA isolated at indicated time points. Slot blot assay was performed 
using antibody for 6-4 photoproducts and percent repair compared to damage achieved 
immediately after exposure (0 Hr).  
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5.3 Discussion 
Mounting evidence places the BER pathway as the most common, and context 
dependent mediator for active DNA demethylation [157, 168].  My data support this 
concept, as I have demonstrated that modulation of multiple components of the BER 
pathway, including GADD45A, TET1, TDG, and PARP-1, impact transcriptional 
upregulation of AREG and EREG. Additionally, the confirmation that AREG and EREG 
enhancers become actively demethylated downstream of integrin α6β4, support active 
DNA demethylation by DNA repair as the mechanism for transcriptional upregulation by 
integrin α6β4. More specifically, GADD45A acts as a rate-limiting step in the activation 
of AREG and EREG and in accordance with the literature, is the coordinating molecule 
for specific DNA demethylation by BER. Interestingly, one study demonstrated that 
GADD45A does not promote DNA demethylation [177]. However, Pfeifer and 
colleagues examined genome-wide DNA demethylation in oocytes and zygotes and this 
broad scale type of regulation seems unlikely for a single molecule [177]. In my study, I 
examine a very specific locus, and foresee GADD45A as a context specific activator of 
gene expression.  
Importantly, I show that TDG specifically, and not MBD4, is required for gene 
expression of AREG and EREG. I also show that recruitment of TDG to the nucleus is 
amplified in cells with high integrin α6β4 expression, suggesting that integrin α6β4 
coordinates steps in this pathway, potentially through nuclear recruitment or specific 
targeting of repair factors. Interestingly, I also examined gene expression levels of DNA 
repair proteins using Qiagen’s DNA damage response qPCR gene array (Appendix B). I 
found that integrin α6β4 does not impact transcription of DNA repair proteins when 
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comparing Panc1-3D7 to Panc1-2G6. This finding supports the hypothesis that integrin 
α6β4 utilizes the DNA repair pathway as opposed to directly modulating transcription of 
the DNA repair components. These data implicate integrin α6β4 as a critical amplifier of 
DNA repair mediated DNA demethylation, identifying a novel mode of transcriptional 
upregulation in response to the integrin.  
Finally, I found that not only can integrin α6β4 utilize BER to promote 
transcriptional upregulation, this integrin also enhances the ability of pancreatic cancer 
cells to respond to and survive in the presence of DNA damage, through both the BER 
and NER pathways. These data support previous studies that demonstrate that tissue 
architecture mediated by integrin α6β4 promotes resolution of double strand breaks 
[178]. Taken together these studies demonstrate that integrin α6β4 contributes to a 
multitude of DNA repair pathways, and may be a key component for connecting the 
extracellular environment with DNA repair mediated nuclear events. These findings have 
major implications considering that the majority of chemotherapeutics currently utilized 
either cause DNA damage or inhibit DNA repair. A better understanding of how integrin 
α6β4 promotes the DNA damage response may assist us in choosing the most effective 
therapies for cancer patients. Therefore, considering the widespread impact that DNA 
repair has on both DNA methylation and cancer progression, I have established integrin 
α6β4 as a key mediator of these tumor-promoting pathways.    
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CHAPTER 6: SUMMARY AND FUTURE DIRECTIONS 
Integrin α6β4 is as a mediator of pro-tumorigenic events in many types of cancer 
including breast, bladder, cervical, head and neck, and pancreas [179]. Additionally, 
many of the downstream signaling pathways that contribute to integrin α6β4 mediated 
invasive properties have been well established. However, aside from studies exploring 
transcription factors such as the NFATs, mechanisms for how integrin α6β4 mediates 
changes in transcriptional profiles have not been explored. In this study, I demonstrated 
that integrin α6β4 contributes to an invasive phenotype of pancreatic cancer cells by 
dramatically upregulating the EGFR ligands AREG and EREG. I found that this 
upregulation is the result of signaling to the NFAT5 transcription factor and active DNA 
demethylation. Interestingly, this DNA demethylation occurred at putative enhancer 
elements in the first intronic region of AREG and EREG. Likewise, using WGBS my 
study revealed that DNA demethylation mediated by integrin α6β4 was not confined to 
site specific changes as seen with AREG and EREG, but promoted genome-wide DNA 
demethylation, a common theme seen throughout cancer progression. Importantly, this 
observation was also manifested in breast cancer cells, but was completely abolished in a 
cell line that lacked the ability to respond to DNA damage. These observations indicated 
that widespread epigenetic regulation mediated by integrin α6β4 occurs in breast and 
pancreatic cancer, two cancers highly dependent on integrin α6β4 signaling [16, 24, 30, 
31]. Therefore, it is reasonable to conclude that DNA demethylation is a common 
mechanism for integrin α6β4’s contribution to an invasive phenotype in cancer cells. 
The loss of alterations in DNA methylation without an intact DNA repair pathway 
provided a plausible mechanism of integrin α6β4 mediated epigenetic events. A thorough 
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examination of the impacts of DNA repair on expression of AREG and EREG revealed a 
dependence on the BER signaling network to promote gene expression. This upregulation 
of AREG and EREG mediated by integrin α6β4 included the molecules TET1, 
GADD45A, PARP1, and TDG. My evidence suggested that this was achieved by specific 
targeting of indicated repair molecules such as TDG to the nucleus. Therefore, I 
concluded that gene specific DNA demethylation, downstream of integrin α6β4 
signaling, is an active process requiring the BER pathway. Additionally, I demonstrated 
that integrin α6β4 enhances the ability of cancer cells to survive in the presence of 
oxidative damage and repair UV induced DNA damage. These findings have major 
implications for cancer treatment. The majority of currently used therapies either cause 
DNA damage or inhibit DNA repair, and therefore integrin α6β4 could play a role in 
chemotherapeutic resistance or patient response.  
My study thoroughly explores the dependence of AREG and EREG on DNA 
demethylation by integrin α6β4. However, to fully elucidate the contributions of integrin 
signaling to the metastatic transcriptome, a more comprehensive approach is necessary. 
Therefore, it will be essential to couple whole genome methylation analysis with whole 
genome RNA-Seq, which is a high throughput method for measuring gene expression, 
where mRNA is isolated, converted to cDNA and whole genome sequencing performed. 
While we can draw conclusions from regions of DNA that become demethylated in 
response to signaling from integrin α6β4, it is critical to compare this information with 
transcriptomic analysis to identify other gene targets that may be similarly regulated. By 
combining these two methods, we can determine if promoter DNA demethylation drives 
gene expression or if changes in more discrete regions, such as non-coding regions, are 
  89 
required as seen with AREG and EREG. This study can be expanded further by 
identifying common mechanisms for gene activation within the breast and pancreatic 
cancer data sets. These common mechanisms for transcriptional regulation by DNA 
demethylation can potentially be identified by exploring shared patterns of altered DNA 
methylation. Additionally, by mining data from different cancer types generated from 
WGBS and RNA-Seq, common signaling pathways that may be upregulated due to DNA 
demethylation could be identified. These data would be critical for establishing common 
mechanisms mediated by integrin α6β4 that contribute to cancer progression and 
tumorigenesis.   
Interestingly, a large proportion (~23%) of the changes in DNA methylation that 
were identified reside in potential enhancer elements, as mapped to acetylation of histone 
H3 at lysine 27 from the Encyclopedia of DNA Elements (ENCODE) project and 
visualized on the UCSC genome browser [180]. However, as previously described 
epigenetic modifications of enhancer elements are dynamic and cell type specific [144]. 
Pancreatic cancer cell lines were not represented by ENCODE, and therefore may not be 
an accurate representation for mapping acetylation patterns. Therefore, to validate the 
findings that integrin α6β4 impacts enhancers, chromatin immunoprecipitation and 
sequencing (ChIP-Seq) will need to be performed for the active enhancer marks 
H3K27Ac and H3K4me1, in cell lines with variable expression of integrin α6β4 and 
compared to marks of DNA demethylation. I expect that alignment of DNA methylation 
with matched ChIP-Seq data will yield even higher numbers of overlapping differentially 
methylated loci with active enhancer elements in integrin α6β4 high expressing cell lines. 
The hypothesis that integrin α6β4 impacts enhancer elements is supported by our 
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investigations of AREG and EREG in pancreas, and S100A4 in breast as DML aligned 
perfectly with potential enhancers identified by ENCODE [30]. There is also the 
likelihood that genes regulated by integrin α6β4 are, at least in part, regulated by super-
enhancers. This idea is supported by the finding that AREG and EREG were associated 
with super-enhancer methylation in multiple myeloma and treatment with low dose 
BRD4 inhibitor, JQ1, dramatically reduced gene expression when integrin α6β4 signaling 
was active [145].  Utilizing ChIP-Seq for BRD4 and the Mediator complex would 
provide a comprehensive analysis of activation of enhancers and super-enhancers by 
integrin α6β4, as BRD4 and Mediator occupancy is much higher in super-enhancers 
[181]. Super-enhancers are especially intriguing in cancer because a single super-
enhancer can regulate entire transcriptional profiles that can mediate cell identity and 
tumorigenesis [145, 182]. Identification of integrin α6β4 as a direct activator of 
enhancers and potentially super-enhancers will have far reaching implications as these 
regulatory elements control gene expression profiles relevant to cancer, including the 
Myc oncogene [145].  
Enhancer elements regulate gene expression through recruitment of transcription 
factors and the mediator complex, often times from long distances [150]. This 
transcriptional regulation comes as the result of chromatin looping, which brings together 
enhancers and promoters, and is dependent on CCCTC-binding factor (CTCF) binding at 
insulator elements [183]. Interestingly, DNA methylation at CTCF binding sites reduces 
the affinity for CTCF binding and therefore decreases chromatin looping, thus reducing 
potential interactions between promoters, enhancers, transcription factors, and epigenetic 
modifiers [184]. Further analysis of our WGBS data revealed 6757 DML, of 259,980 
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CTCF binding sites that contain at least 1 CpG site as identified by ENCODE. However, 
DNA methylation is not the only factor impacting CTCF binding. Therefore, 
investigating both DNA methylation and CTCF binding ability, downstream of integrin 
α6β4 signaling, by ChIP-seq, will provide a more comprehensive view of DNA 
demethylation induced transcriptional regulation. Also, to address the impact of integrin 
α6β4 on chromatin looping, chromosome confirmation capture (3C) methods could be 
performed. 3C allows for identification of regions of chromatin that are connected by 
large protein complexes, such as CTCF, and therefore determine chromatin regions that 
are in close proximity. This technique is of interest to my study because of the broad 
scale impact of integrin α6β4 on the epigenome. 3C will also allow us to identify what 
enhancer elements are in close proximity to integrin α6β4 regulated genes such as AREG 
and EREG. I expect that integrin a6b4 will have broad impacts on the epigenome, 
including chromatin looping and enhancer interactions. Therefore, if enhancers or CTCF 
binding sites are indeed a common target of DNA demethylation by integrin α6β, these 
alterations in DNA demethylation may have much broader reaching impacts on 
transcription than were originally anticipated. These findings would therefore have the 
potential to identify integrin α6β4 as a critical epigenetic modifier specific for metastatic 
growth. Broad reaching changes in the epigenome mediated by a sensor of the tumor 
microenvironment, integrin α6β4, could have major implications for targeting advanced 
stage disease, and therefore patient mortality.  
Expanding on the requirement of effective DNA damage repair to achieve DNA 
demethylation downstream of integrin α6β4 signaling, my data revealed that AREG and 
EREG expression is dependent on an intact BER signaling network. To determine if 
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integrin α6β4 regulated gene expression of DNA repair molecules, I examined gene 
expression levels by qPCR array and found no significant alterations in gene expression 
mediated by integrin α6β4 (Appendix B).  This lack of transcriptional regulation on DNA 
repair proteins is surprising when considering the broad impact that integrin α6β4 has on 
gene expression and its utilization of DNA repair to activate DNA demethylation. 
Therefore, I hypothesize that integrin α6β4 is contributing to DNA demethylation by 
targeting the DNA repair molecules to specific regions for demethylation. This concept 
could be examined first at the AREG and EREG enhancers by looking for occupancy of 
DNA repair proteins by ChIP analysis, within their respective regions of altered DNA 
methylation. If continued signaling were required to maintain a hypomethylated state 
then I would expect that at least TET, TDG, and GADD45A would reside in some of 
these sites for DNA demethylation. Targeted localization of DNA repair proteins by 
integrin α6β4 could be expanded further, as I would anticipate genome-wide occupancy 
downstream of integrin α6β4, considering the broad impact integrin α6β4 has on DNA 
demethylation. This hypothesis can be tested by utilizing cellular fractionation 
experiments, where proteins are isolated from the cytoplasm, nucleus, and chromatin and 
western blot analysis used to detect protein levels. Additionally, ChIP-Seq analysis for 
DNA repair proteins downstream of integrin α6β4 would determine if integrin α6β4 
upregulated genes are indeed targets for these DNA repair complexes. Coupling these 
data with RNA-Seq and WGBS will provide confirmation that targeting of the BER 
machinery is indeed what drives expression of integrin α6β4 upregulated genes. I expect 
that a proportion of these genes will indeed align with altered sites in DNA methylation. 
However, because other DNA repair pathways have been implicated in DNA 
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demethylation, it is likely that genes are regulated differently in response to different 
situations or stimuli.  
 In this study, I showed that knockdown of TET1 resulted in a corresponding 
decrease in AREG and EREG expression. However, this decrease was not always 
consistent. Importantly, three TET proteins have currently been identified, TET1, TET2, 
and TET3, all of which have also been implicated in DNA demethylation, as they too 
have enzymatic activity towards 5-mC [185]. However, how the TET family of proteins 
differs in their substrate specificity has not been fully elucidated, specifically in cancer. 
We do know that TET proteins are commonly mutated in blood-derived cancers and less 
often in solid tumors, but evidence suggests that these mutations can indeed act as drivers 
of tumor progression [186]. Additionally, a decrease in expression of TET proteins, and 
subsequent 5-hmC reductions, has been implicated in tumor growth and metastasis [187], 
indicating that regulation of these proteins may offer a potential explanation for integrin 
α6β4 mediated DNA demethylation. In my system, expression levels of the different TET 
family members will need to be elucidated, in order to more completely understand how 
integrin α6β4 impacts the DNA demethylation cascade.  
While levels of TET proteins are certainly important, the field is just beginning to 
understand how 5-mC derivatives are localized across the genome and how they 
contribute to cancer. 5-hmC has been preferentially found at enhancers and gene body 
elements in embryonic stem cells [188-190]. Considering that about 23% of the DML 
found in response to integrin α6β4 are located at potential enhancer elements, 5-hmC 
may therefore be of importance for integrin α6β4 facilitated DNA methylation and DNA 
demethylation. Importantly, bisulfite sequencing cannot distinguish between 5-mC and 5-
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hmC, and 5-fC and 5-caC appear as unmethylated cytosines. This is an important 
observation, as my study fails to accurately capture dynamic modifications of 5-mC 
taking place in response to integrin α6β4.  Fortunately, with the recent development of 
state of art techniques to discriminate between 5-mC derivatives. Use of antibody based 
sequencing methods to specifically test 5-hmC, 5-fC, and 5-caC localization across the 
genome will help to uncover the interplay between such DNA demethylation reactions. 
Lastly, knockdown of the individual TET molecules by shRNA and assessment of 
methylation patterns by WGBS downstream of integrin α6β4 may help to reveal which of 
these proteins is indeed responsible for DNA demethylation downstream of integrin α6β4 
signaling. The current literature demonstrates the importance of all three TET proteins, 
but how they differ in their activation of gene expression is still unknown. We may be 
able to unveil a context dependent targeting mechanism of the TET proteins if integrin 
α6β4 mediated DNA demethylation proceeds through a specific TET, or targets DNA 
demethylation to a specific region through the TET proteins.  
Lastly, the TET proteins and DNA glycosylases have an interdependent 
relationship, as cooperativity between these molecules is required for active DNA 
demethylation by DNA repair [164, 168, 191, 192]. Interestingly, TDG has a preference 
for binding and removal of 5-caC and 5-fC but has no intrinsic enzymatic activity 
towards or ability to bind 5-hmC [191]. TDG’s preference for these substrates supports 
my data that GADD45A is necessary for removal of 5-mC, as it must act as the 
intermediate step between TET and TDG [162, 164]. Additionally, this would suggest 
that the demethylation reaction of AREG and EREG can proceed through all three 5-mC 
intermediates, as TDG can rapidly remove 5-fC and 5-caC without the activity of 
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GADD45A [192]. This reliance of TDG on GADD45A for removal of 5-hmC explains 
why other DNA glycosylases may also be required as MBD4 can directly act on 5-hmC, 
and would therefore be a more efficient process for removal [163, 169]. I did test the 
dependence of AREG and EREG on MBD4 and found no change in gene expression, 
thus supporting my hypothesis that GADD45A is required. Considering that the TETs are 
responsible for initiating the process of DNA demethylation and the newly found 
importance of 5-mC derivatives in cancer, it is possible that signaling to these molecules 
could indeed be how gene specific DNA demethylation, and subsequent gene activation 
is achieved in response to integrin α6β4 signaling [159, 167, 186, 188, 191].  
 The majority of investigations examining the role of DNA repair on DNA 
methylation have done so in the context of genome wide reprogramming or by using in 
vitro reporter systems [163, 193, 194]. My study, demonstrating the dependence of 
AREG and EREG on the BER pathway in response to a specific stimulus, integrin α6β4, 
is unique in that it assessed context dependent DNA demethylation by DNA repair in 
pancreatic cancer cell lines. A previous study done in MDA-MB-231 breast cancer cells 
examined the pS2 promoter in response to Estrogen Receptor alpha signaling and reveled 
a dual role for the de novo methyltransferases DNMT3a/3b, during cyclical methylation 
and demethylation following stimulation with estradiol [195]. Expectedly, during a 
repressive state DNMT3a/3b acted in cooperation with DNMT1 to cause gene 
methylation, and therefore silencing [196]. However, during demethylation, DNMT3a/3b 
and TDG were coordinately recruited to CpG sites where the methyltransferases acted as 
a deaminating agent at 5-mC similar to the AID and APOBEC proteins. This deamination 
in turn recruited the remainder of the BER complex of proteins including PARP-1, 
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resulting in active DNA demethylation. This study is particularly interesting considering 
that AID, the most common mediator of cytosine deamination [197], is not detectable in 
any of the pancreatic cancer cell lines that I examined (data not shown). These findings 
that DNMT3a/3b can act as the deaminating agent, may provide an explanation for the 
missing link in my study for how rapid, context dependent DNA demethylation could be 
achieved. This study is also pertinent to my work with the finding that integrin α6β4 
recruits TDG to the nucleus, and work done by Yun et al. demonstrating that EREG is 
epigenetically silenced by DNA methylation in gastric cancer by DNMT3b [110]. 
Therefore, this switch in repressive and activating functions mediated by TDG and 
DNMT3a/3b could be a potential mechanism for activation of AREG and EREG in 
metastatic cancer cells. Further analysis of the dependence of AREG and EREG on 
DNMT3a/3b by knockdown and overexpression experiments, as well as ChIP analysis 
examining TDG and DNMT3a/3b localization to promoter regions, downstream of 
integrin α6β4 would be required to confirm this hypothesis.  
In conclusion, this study examines a very specific sensor of the tumor 
microenvironment, integrin α6β4, and provides an exciting new role for this molecule in 
promoting tumor progression. The data presented in this dissertation offer a novel 
mechanism for the upregulation of tumor promoting genes, alterations in the epigenome, 
and utilization of DNA repair, and taken together places integrin α6β4 as a major 
regulator of cancer epigenetics. These findings have far reaching impacts on our 
understanding of pancreatic carcinoma. Further analysis of integrin α6β4’s role in these 
processes could yield a broad understanding for how the tumor microenvironment 
impacts gene regulation in cancer.     
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APPENDICES 
Appendix: List of Acronyms and Abbreviations  
3C Chromatin Conformation Capture 
5-Aza-CdR 5-Aza-2’-Deoxycytidine 
5-caC 5-Carboxylcytosine 
5-fC 5-Formylcytosine 
5-hmC 5-hydroxymethylcytosine 
5-mC 5-methylcytosine 
6-4PP 6-4 Photoproducts 
ADAM Disintegrin and metalloproteinase domain-containing protein  
AID Activation Induced Cytidine Deaminase 
APE Apurinic/Apyrimidinic Endonuclease 
APOBEC Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 
AREG Amphiregulin 
ATCC American Type Culture Collection 
B-CIMP Breast – CpG Island Methylator Phenotype 
BER Base Excision Repair 
bp Base Pairs 
BRD4 Bromodomain-containing protein 4 
BSA Bovine Serum Albumin 
ChIP-Seq Chromatin Immunoprecipitation and Sequencing 
CTCF CCCTC-Binding Factor 
DAC 5-Aza-2’Deoxycytidine 
DMEM Dulbecco’s Modified Eagle Medium 
DML Differentially Methylated Loci 
DMR Differentially Methylated Region 
DMSO Dimethyl Sulfoxide 
DNMT DNA methyltransferase 
DPQ 5-(4-Piperidin-1-ylbutoxy)-3,4-dihydro-2H-isoquinolin-1-one 
ECM Extracellular Matrix 
EGF Epidermal Growth Factor 
EGFR Epidermal Growth Factor Receptor 
ELISA Enzyme-linked Immunosorbent Assay 
EMT Epithelial-Mesenchymal Transition 
ENCODE Encyclopedia of DNA Elements 
EREG Epiregulin 
GADD45A Growth Arrest and DNA Damage Inducible Protein Alpha 
HAT Histone Acetyltransferases 
HDAC Histone Deacetylases 
HGF Hepatocyte Growth Factor 
HR Homologous Recombination 
ITGB4 Integrin Beta 4 
MBD4 Methyl-binding Protein 4 
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MET Mesenchymal Epithelial Transition Factor 
MMP Matrix Metalloproteinase 
MTA Metastasis-Associated Gene 
MTT 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyl-2H-tetrazolium bromide 
NER Nucleotide Excision Repair 
NFAT Nuclear Factor of Activated T-Cells 
NHEJ Non-homologous End Joining 
NuRD Nucleosome Remodeling Deacetylase 
PARP Poly ADP Ribose Polymerase 
PBS Phosphate Buffered Saline 
PCR Polymerase Chain Reaction 
qPCR Quantitative Real-time PCR 
RNA-Seq RNA Sequencing (Whole Transcriptome Shotgun Sequencing) 
RPMI Roswell Park Memorial Institute 
RT-PCR Reverse Transcription PCR 
SAM S-adenosylmethionine 
shRNA Short Hairpin RNA 
TACE Tumor necrosis factor α converting enzyme 
TBST Tris Buffered Saline with Tween-20 
TCGA The Cancer Genome Atlas 
TDG Thymine DNA Glycosylase 
TET Ten Eleven Translocase Methylcytosine Dioxygenase 
TGFα Transforming Growth Factor alpha 
TSA Tricostatin A 
TSS Transcription Start Site 
WGBS Whole Genome Bisulfite Sequencing 
XPA Xeroderma Pigmentosum Complementation Group A 
XPF Xeroderma Pigmentosum Complementation Group F 
XPG Xeroderma Pigmentosum Complementation Group G 
XRCC X-Ray Repair Cross Complementing Protein 
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APPENDIX B: Expression Changes in DNA Repair Genes Altered in Panc1-3D7 
Compared to Panc1-2G6 Cell Lines 
Gene 
Symbol 
Gene Name Relative 
Expression  
ABL1 C-abl oncogene 1, non-receptor tyrosine kinase 1.044213314 
APEX1 APEX nuclease (multifunctional DNA repair enzyme) 1 0.744543961 
ATM Ataxia telangiectasia mutated 1.003391833 
ATR Ataxia telangiectasia and Rad3 related 0.708281175 
ATRIP ATR interacting protein 0.93481345 
ATRX Alpha thalassemia/mental retardation syndrome X-linked 1.229314328 
BARD1 BRCA1 associated RING domain 1 1.361890233 
BAX BCL2-associated X protein 0.628303275 
BBC3 BCL2 binding component 3 1.343241482 
BLM Bloom syndrom, RecQ helicase-like 1.045129004 
BRCA1 Breast cancer 1, early onset 0.911443208 
BRIP1 BRCA1 interacting protein C-terminal helicase 1 0.880585152 
CDC25A Cell division cycle 25 homolog A (S. pombe) 0.909411445 
CDC25C Cell division cycle 25 homolog C (S. pombe) 1.114727422 
CDK7 Cyclin-dependent kinase 7 0.840416509 
CDKN1A Cyclin-dependent kinase inhibitor 1A (p21, Cip1) 0.877608682 
CHEK1 CHK1 checkpoint homolog (S.Pombe) 0.800566298 
CHEK2 CHK2 checkpoint homolog (S.Pombe) 0.972928527 
CIB1 Calcium and integrin binding 1 (calmyrin) 0.886807553 
CRY1 Cryptochrome 1 (photolyase-like) 0.604707568 
CSNK2A2 Casein kinase 2, alpha prime polypeptide 1.110699585 
DDB1 Damage-specific DNA binding protein 1, 127 kDa 0.75852527 
DDB2 Damage-specific DNA binding protein 2, 48 kDa 0.531650127 
DDIT3 DNA-damage-inducible transcript 3 0.940031062 
ERCC1 Excision repair cross-complementing rodent repair 
deficiency, complementation group 1 (includes 
overlapping antisense sequence) 
1.023529406 
ERCC2 Excision repair cross-complementing rodent repair 
deficiency, complementation group 2 
0.662243662 
EXO1 Exonuclease 1 1.084799341 
FANCA Fanconi anemia, complementation group A 0.956634252 
FANCD2 Fanconi anemia, complementation group D2 0.900801848 
FANCG Fanconi anemia, complementation group G 0.693765162 
FEN1 Flap structure-specific endonuclease 1 1.177500516 
GADD45A Growth arrest and DNA-damage inducible alpha 0.951023937 
GADD45G Growth arrest and DNA-damage inducible gamma 0.436125383 
H2AFX H2A histone family, member X 0.898123871 
HUS1 HUS1 checkpoint homolog (S. pombe) 0.789979815 
LIG1 Ligase 1, DNA, ATP-dependent 0.896882724 
MAPK12 Mitogen0activated protein kinase 12 0.991326953 
MBD4 Methyl-CpG binding domain protein 4 0.723859414 
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MCPH1 Microcephalin 1 0.932268511 
MDC1 Mediator of DNA-damage checkpoint 1 0.662076456 
MLH1 MutL homolog 1, colon cancer, nonpolyposis type 2 (E. 
coli) 
1.012075698 
MLH3 MutL homolog 3 (E. coli) 0.993774251 
MPG N-methylpurine-DNA glycosylase 0.859434853 
MRE11A MRE11 meiotic recombination 11 homolog A (S. 
cerevisiae) 
1.020942692 
MSH2 MutS homolog 2, colon cancer, nonpolyposis type 1 (E. 
coli) 
0.885157144 
MSH3 MutS homolog 3 (E. coli) 0.854446539 
NBN Nibrin 0.656992125 
NTHL1 Nth endonuclease III-like 1 (E. coli) 0.711448585 
OGG1 8-oxoguanine DNA glycosylase 0.751265677 
PARP1 Poly (ADP-ribose) polymerase 1 0.822862726 
PCNA Proliferating cell nuclear antigen 0.703500209 
PMS1 PMS1 postmeiotic segregation increased 1 (S. cerevisiae) 0.783003843 
PMS2 PMS2 postmeiotic segregation increased 2 (S. cerevisiae) 0.772485157 
PNKP Polynucleotide kinase 3'-phosphatase 0.846781494 
PPM1D Protein phosphatase Mg2+/Mn2+ dependent, 1D 1.015749914 
PPP1R15A Protein phosphatase 1, regulatory (inhibitor) subunit 15A 0.647809011 
PRKDC Protein kinase, DNA-activated, catalytic polypeptide 0.64865145 
RAD1 Rad1 homolog (S. pombe) 1.328684268 
RAD17 Rad17 homolog (S. pombe) 0.846117886 
RAD18 Rad18 homolog (S. cerevisiae) 0.918199225 
RAD21 Rad21 homolog (S. pombe) 1.18871857 
RAD50 Rad50 homolog (S. cerevisiae) 0.938131515 
RAD51 Rad51 homolog (S. cerevisiae) 0.8296814 
RAD51B Rad51 homolog B (S. cerevisiae) 0.808202915 
RAD9A Rad9 homolog A (S. pombe) 0.744588258 
RBBP8 Retinoblastoma binding protein 8 0.434280749 
REV1 REV1 homolog (S. cerevisiae) 1.058816921 
RNF168 Ring finger protein 168 0.796362795 
RNF8 Ring finger protein 8 0.899685452 
RPA1 Retinoblastoma binding protein 8 0.858602396 
SIRT1 Sirtuin 1 0.60205756 
SMC1A Structural maintenance of chromosomes 1A 0.751273622 
SUMO1 SMT3 suppressor of mif two 3 homolog 1 (S. cerevisiae) 0.916437083 
TOPBP1 Topoisomerase (DNA) II binding protein 1 0.709179752 
TP53 Tumor protein p53 1.047393357 
TP53BP1 Tumor protein p53 binding protein 1 0.962333642 
TP73 Tumor protein p73 1.731093414 
UNG Uracil-DNA glycosylase 0.952124731 
XPA Xeroderma pogmentosum, complementation group A 0.926444599 
XPC Xeroderma pogmentosum, complementation group C 0.836594181 
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XRCC1 X-ray repair complementing defective repair in Chinese 
hamster cells 1 
0.803931679 
XRCC2 X-ray repair complementing defective repair in Chinese 
hamster cells 2 
0.654023059 
XRCC3 X-ray repair complementing defective repair in Chinese 
hamster cells 3 
0.557330553 
XRCC6 X-ray repair complementing defective repair in Chinese 
hamster cells 6 
0.971698333 
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